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Abstract
Feasibility and Efficacy of Virtual Darkness in Reducing Intra-Individual Variability of
Sleep Parameters among Young Adults with Insomnia
by
Samantha Sherwood
Dr. Daniel Allen, Committee Chair
Professor of Psychology
University of Nevada, Las Vegas
Background
Insomnia impacts 30% of people and is associated with increased risk for medical and
psychiatric illness. However, pharmacological treatments for sleep yield mixed results and often
result in undesirable side effects indicating a need for novel insomnia interventions. Sleep
patterns also demonstrate high intraindividual variability which may be associated with greater
daytime impairment, and sleep-wake cycles are strongly affected by the timing of exposure to
blue-green wavelength light. Virtual darkness, a novel intervention, blocks blue wavelength light
from reaching the eye to simulate actual darkness on retinal cells sensitive to light. Therefore, the
purpose of the current study is to examine whether virtual darkness is a feasible intervention to
improve insomnia symptoms and decrease sleep variability.
Methods
Participants were young adults with moderate to severe insomnia and were randomized to
one of three treatment conditions in a double-blind, placebo-controlled, crossover design.
Participants wore clear glasses (placebo) or blue-light filtering glasses (virtual darkness) for three
hours prior to bedtime and completed a sleep diary and mood questionnaire each morning.
Participants texted a selfie to monitor compliance with wearing the study glasses each night and
reported side effects weekly. Mixed-effects location-scale models (MELSM) were used to assess
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whether virtual darkness improved total sleep time (TST), sleep efficiency (SE), sleep onset
latency (SOL), number of times waking after sleep onset (WASO), sleep quality, and mood,
calmness, and energy upon waking
Results
On average, participants demonstrated 90% compliance with wearing the study glasses.
The most common intervention-related side effects were mild eye strain and head pressure while
wearing the placebo and active treatment glasses. MELSM results indicated that participants’
SOL significantly improved with treatment such that participants fell asleep faster during the
virtual darkness phase compared to placebo. Participants also had decreased WASO, better selfreported sleep quality, more positive mood upon waking, and greater calmness upon waking
during the virtual darkness phase. Intra-individual variability of SOL also improved with SOL
becoming 47% more consistent during the virtual darkness phase compared to placebo. Virtual
darkness did not significantly impact TST, SE, or energy upon waking.
Conclusions
Preliminary results suggest that virtual darkness may represent a promising low-cost
intervention for insomnia symptoms. Treatment with virtual darkness resulted in clinically
meaningful improvements in sleep outcomes.
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Chapter 1: Literature Review
High-quality sleep is an important factor in promoting optimal daytime functioning and
health across the lifespan. Unfortunately, many youth and adults report poor-quality sleep on a
regular basis (Buboltz et al., 2001; Centers for Disease Control and Prevention, 2011; Kann et
al., 2014; Lund et al., 2010). Several pharmacological and psychotherapeutic sleep interventions
have been developed to treat sleep difficulties such as insomnia. Each of these interventions
demonstrate efficacy in improving some sleep parameters (e.g., sleep onset latency) but not
others, and are often associated with high costs and undesirable side effects (Blake et al., 2017;
Perlis & Smith, 2008; Sateia et al., 2017; Schutte-Rodin et al., 2008; Smith et al., 2002;
Zachariae et al., 2016). Existing sleep intervention research has typically used weekly averages
of sleep parameters to assess for improvement in sleep. This is problematic because sleep
appears to display high intraindividual variability (IIV) (Knutson et al., 2007; van Hilten et al.,
1993). Greater IIV is associated with increased daytime impairment (Becker et al., 2017) and
behavioral difficulties (Bates et al., 2002), and existing sleep interventions demonstrate efficacy
in reducing some aspects of sleep IIV but not others (Becker et al., 2017; Bei et al., 2016).
Therefore, development of a cost-effective and tolerable sleep intervention that reduces IIV has
the potential to meet a significant public health need. The present study aimed to (1) examine the
feasibility of virtual darkness as a novel treatment for insomnia, (2) determine whether treatment
with virtual darkness is effective in reducing IIV of sleep parameters and daily mood, and (3)
assess whether individuals with greater IIV experience more impairment in daytime functioning.
Sleep Disturbance
Sleep is a fundamental mechanism that facilitates important processes such as energy
conservation, homeostasis, and memory consolidation (Brand & Kirov, 2011). Getting an
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adequate amount of sleep each night is associated with a myriad of positive effects, such as
improved cognitive functioning (Araújo & Almondes, 2014) and physical health outcomes (Chen
et al., 2006). Sleep deprivation, however, is common across the lifespan. Over 35% of adults
report receiving less than seven hours of sleep on average (Centers for Disease Control and
Prevention, 2011), while almost 70% of adolescents (Kann et al., 2014) report receiving less than
eight hours of sleep on average. Older adults are recommended to sleep at least seven hours per
day (Consensus Conference Panel, 2015), while adolescents are recommended to sleep eight to
ten hours per day (Paruthi et al., 2016). Sleep difficulties are also common among young adults,
with over 60% of university undergraduate students reporting poor-quality sleep (Lund et al.,
2010) and over 50% reporting morning tiredness due to disrupted sleep (Buboltz et al., 2001).
Young adults in particular may require at least nine hours of sleep each day in comparison with
the seven or more hours recommended for older adults (Consensus Conference Panel, 2015).
Between 7.7 and 13.1% of young adult undergraduate students meet full criteria for an insomnia
disorder (Nadorff et al., 2011; Schlarb et al., 2012; Taylor et al., 2011, 2013), indicating
significant problems with falling asleep, staying asleep, or waking too early (or a combination of
these difficulties) at least three nights per week for at least three months (American Psychiatric
Association, 2013). In summary, sleep disturbance and insomnia impact a significant portion of
the general population.
Sleep disturbance is associated with a variety of chronic and acute problems in overall
health and daytime functioning. Insomnia is related to a greater incidence of risky decisionmaking (Harrison & Horne, 2000), fatigue-related accidents (de Mello et al., 2013), and greater
risk for physical health conditions such as cancer, obesity, cardiovascular disease, and diabetes
(Harvey et al., 2011; Zelinski et al., 2014). Individuals with chronic insomnia report lower
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overall quality of life compared to normal sleepers (Taylor et al., 2013), and sleep disturbance is
associated with more conflict and less empathy within intimate relationships (Gordon & Chen,
2014). Insomnia is also associated with impairments in daytime cognitive functioning including
problems with learning, memory, and executive functioning among adults (Fortier-Brochu et al.,
2012) and youth (Astill et al., 2012). Both youth and undergraduate students with disturbed sleep
demonstrate lower academic performance (e.g., lower GPAs) (Gaultney, 2010; Ming et al.,
2011), and report greater daytime fatigue and difficulty with attention and concentration (Alapin
et al., 2000) compared to peers without sleep problems. For youth who use blue-light emitting
electronic devices (e.g., mobile phones) prior to bed, sleep difficulties are even more pronounced
(Ferreira et al., 2017; Nose et al., 2017), which may in turn result in increased daytime fatigue
(Ferreira et al., 2017) and decreased daytime cardiac autonomic nervous system functioning
upon waking (Nose et al., 2017) compared to youth who do not use blue-light emitting devices
before bed. Therefore, sleep problems play a vital role in daytime functioning and physical
health outcomes across the lifespan.
Sleep disturbance and mental health. In addition to high prevalence in the general
population, sleep disturbance is also associated with a number of psychiatric conditions,
including anxiety disorders (Monti & Monti, 2000; Ohayon & Lemoine, 2002; Overbeek et al.,
2005; Simon et al., 2016; Stein et al., 1993), attention deficit/hyperactivity disorder (LunsfordAvery et al., 2016; Ramnaraine et al., 2016; Spruyt & Gozal, 2011), psychotic disorders
(Benson, 2006; Khurshid, 2018; Monti & Monti, 2005), substance use disorders (Khurshid,
2018), and post-traumatic stress disorder (Ohayon & Shapiro, 2000). Sleep disturbance is a
common symptom of mood disorders, including major depressive disorder (Brand & Kirov,
2011; Rao et al., 2009) and bipolar disorder (Bauer et al., 2006; Plante & Winkelman, 2008).
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Among adults treated with cognitive behavioral therapy (CBT) or pharmacotherapy for major
depressive disorder, 88% endorse experiencing sleep difficulties at baseline (Carney et al., 2007).
Among individuals with bipolar disorder, 69 to 99% report decreased need for sleep during
(hypo)manic episodes and 78 to 100% experience disturbed sleep during depressive episodes
(Harvey et al., 2009).
Beyond a high rate of co-occurrence with many psychiatric problems, current findings
suggest the presence of a bi-directional relationship between sleep problems and mood disorders
specifically. Adolescents who meet criteria for an insomnia disorder demonstrate a four- to fivefold increase in the odds of reporting depression. Depressed youth report significantly shorter
total sleep time (TST) and time in bed (TIB), significantly longer sleep onset latency (SOL) and
wakings after sleep onset (WASO), and lower habitual sleep efficiency (SE) compared to youth
without depression (Sivertsen et al., 2014). Sleep dysregulation may also occur as a prodromal
symptom of (hypo)manic episodes and contribute to the onset of both (hypo)manic and
depressive episodes among individuals with bipolar disorder (Gershon et al., 2017; Harvey et al.,
2009). Furthermore, sleep problems may worsen existing psychiatric symptoms (Khurshid,
2018) and are associated with an increased risk for suicidal ideation and attempts (Bernert et al.,
2015; Fitzgerald et al., 2011; Pigeon et al., 2012). Given the high prevalence of electronic device
usage at bedtime, some researchers have proposed nighttime technology use as one factor that
may result in both sleep disturbance and suicidal ideation (Polos et al., 2015). Use of technology
to communicate with others (e.g., through texting or messaging) has been linked to sleep
disruption (Polos et al., 2015) and increases in cyberbullying (Twenge, 2020), which may in turn
be associated with greater suicidality. While bedtime technology use may be linked to poorer
sleep and suicidality, the relationship between sleep and suicidality has been documented since
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the 1970s (Pigeon et al., 2012), which pre-dates the advent of modern electronic devices and
suggests a unique relationship between sleep disturbance and suicidality. Despite the increased
risk of suicidal ideation and psychiatric conditions following sleep problems, current
interventions often do not significantly improve insomnia symptoms. For example, among
individuals treated for depression, sleep difficulties often persist even after remittance of other
depressive symptoms (Carney et al., 2007). Therefore, many individuals may require additional
sleep-focused intervention to help resolve sleep disturbances that co-occur with suicidal ideation
and other psychiatric disorders in order to prevent worsening of symptoms or onset of new
symptoms.
Access to effective treatment for sleep problems that prevent the onset or worsening of
psychiatric symptoms might be particularly important for adolescents and young adults.
Although sleep difficulties impact individuals across the lifespan, adolescence and young
adulthood are the primary periods of onset for many psychiatric disorders (Kessler et al., 2005)
and are also periods of time in which sleep-wake cycle delays occur for both biological and
social reasons. Biologically, sleep phase delay occurs when the timing of an adolescent’s sleepwake pattern shifts significantly later than observed during childhood (Carskadon et al., 1993;
Carskadon & Acebo, 2002) and follows puberty (Carskadon & Acebo, 2002). Adolescents’
social demands, however, do not change as their sleep-wake patterns shift. Although adolescents
are biologically predisposed to fall asleep later and wake up later due to a delayed sleep phase,
school start times remain early in the morning which may significantly reduce sleep duration and
increase daytime fatigue (Wolfson et al., 2007). Over 50% of adolescents with delayed sleep
phase also meet criteria for insomnia (Sivertsen et al., 2013). Left untreated, insomnia and other
sleep problems may persist into young adulthood. This is problematic because young adults are
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already at greater risk for initial onset of psychopathology compared to other age groups (Kessler
et al., 2005), and sleep problems often precede and contribute to the initial onset of psychiatric
disorders in this population (Buysse et al., 2008). Therefore, given the substantial impact of sleep
difficulties on functioning among adolescents and young adults, development of a low-cost
treatment that improves insomnia symptoms has the potential to meet a significant public health
need for this population.
Current Sleep Interventions
A number of pharmacological interventions are already available to improve sleep
duration, quality, and daytime functioning. Pharmacological treatment for insomnia typically
involves classes of medications including benzodiazepines (e.g., triazolam), nonbenzodiazepine
hypnotics (e.g., zolpidem), melatonin receptor agonists (e.g., ramelteon), antidepressants with
sedative effects (e.g., trazodone), melatonin, or combination pharmacotherapy (Lie et al., 2015;
Matheson & Hainer, 2017; Schutte-Rodin et al., 2008). In efficacy trials, benzodiazepines appear
to slightly decrease SOL and increase TST compared to placebo (Holbrook et al., 2000).
Nonbenzodiazepine hypnotics have demonstrated efficacy in decreasing WASO and SOL, and
improving SE and TST when compared to placebo (Lie et al., 2015; Nowell et al., 1997).
Melatonin agonists reduce SOL when compared to placebo, but do not appear to produce
significant improvements in other sleep parameters (Mini et al., 2007; Zammit et al., 2007).
Antidepressants with sedative effects have shown efficacy in increased TST and decreased
WASO (Lie et al., 2015). Treatment with melatonin has produced mixed results in placebocontrolled trials, with some studies indicating improvements in sleep parameters following
melatonin supplementation but other studies demonstrating no effect compared to placebo

6

(Sateia et al., 2017). In summary, several pharmacological interventions appear effective in
improving some, but not all, insomnia symptoms.
Although pharmacological interventions appear to improve certain symptoms of
insomnia, drug treatment is associated with several undesirable side effects. Patients prescribed
benzodiazepines may experience daytime fatigue, dizziness, and memory problems (Holbrook et
al., 2000). Benzodiazepines are also Schedule IV controlled substances, indicating that they may
become addictive if used long-term (Lie et al., 2015). While many nonbenzodiazepine hypnotics
do not appear as addictive as benzodiazepines, they produce a number of adverse effects,
including nightmares, irritability and agitation, dizziness, and drowsiness (Dang et al., 2010).
Melatonin agonists are associated with drowsiness, dizziness, and nausea, while antidepressants
with sedative effects are associated with drowsiness and headaches (Lie et al., 2015). Melatonin
supplements may be associated with drowsiness, dizziness, headaches, and nausea (Andersen et
al., 2016). Furthermore, due to the brief nature of drug trials, data regarding the long-term
efficacy of pharmacotherapy for insomnia is lacking (Smith et al., 2002). Therefore, while
several pharmacological treatments may be effective for short-term management of insomnia,
these interventions may result in undesirable side effects and long-term treatment outcomes are
unclear.
Behavioral sleep interventions, such as cognitive behavioral therapy for insomnia (CBTI), have been developed as an alternative to pharmacological treatments. CBT-I typically
involves skill-based components including sleep hygiene, stimulus control, sleep restriction,
relaxation, and cognitive therapy (Blake et al., 2017). CBT-I demonstrates good efficacy in
improving SOL, WASO, SE (Blake et al., 2017; Trauer et al., 2015), and subjective sleep quality
(Kodsi et al., 2019; Murawski et al., 2018). Cognitive behavioral interventions for sleep
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problems have demonstrated long-term positive outcomes after therapy has concluded (Sivertsen
et al., 2006) and are well-tolerated by patients with minimal to no side effects (Blake et al.,
2017). CBT-I, however, may not significantly improve some important aspects of insomnia, such
as short TST (Blake et al., 2017; Trauer et al., 2015). There are several barriers to accessing
psychotherapy services including the high cost of participating in weekly therapy sessions and
significant difficulty locating a therapist trained in administering CBT-I or other evidencesupported interventions for sleep problems (Perlis & Smith, 2008; Zachariae et al., 2016). Given
the high cost and difficulty accessing effective psychotherapy interventions, and the undesirable
side effects of pharmacological treatment, it is important to identify novel interventions for
insomnia that may be more cost-effective, tolerable, and scalable to the general population.
Intervention with virtual darkness. One potential pathway for the treatment of
insomnia involves regulation of light and darkness cues in a person’s environment. Sleep-wake
cycles are regulated by biological processes that are influenced by an individual’s environment
and behavior. In particular, biological sleep processes are directly regulated by light cues from
the environment. Light cues are received by specialized retinal receptors known as intrinsically
photosensitive retinal ganglion cells (ipRGCs) that are sensitive to light in the violet to blue
wavelength spectrum (Foster et al., 1991; Wong et al., 2005). ipRGCs transmit light information
to the suprachiasmatic nucleus (SCN) and pineal gland. The transmission of blue wavelength
light cues results in the suppression of melatonin production, resulting in increased alertness.
Alternatively, the lack of signaling of light cues (i.e., during nighttime periods) to the SCN and
pineal gland stimulates production of melatonin, resulting in decreased alertness and increased
drowsiness (Foster et al., 1991; Wong et al., 2005). Following lack of signaling of light cues,
melatonin levels increase prior to and throughout sleep (Ardura et al., 2003). However, exposure
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to blue wavelength light during this period suppresses melatonin production (Brainard et al.,
2001; West et al., 2010) and increases alertness (Phipps-Nelson et al., 2009). In modern society,
exposure to blue light has become increasingly common during both day and nighttime hours via
electronic use (e.g., smart phones, tablets, computers, etc.) and some types of energy-efficient
lighting (e.g., LED lightbulbs). Use of blue light emitting devices prior to bedtime suppresses
melatonin production and increases alertness (Chinoy et al., 2018). Longer exposure to blue light
from these sources prior to attempting sleep is associated with longer SOL and poorer sleep
quality (Chang et al., 2015; Christensen et al., 2016). A potential method for improving sleep
problems while accommodating modern life is to prevent blue wavelength light from reaching an
individual’s ipRGCs, thereby creating a state of “virtual darkness.”
Prior research has examined dark therapy as a method for blocking blue wavelength light
and stimulating melatonin production. Dark therapy is conducted by keeping an individual in a
completely dark room without light exposure for an extended period (commonly between 6pm to
8am) and has primarily been examined as an intervention for sleep dysregulation in bipolar
disorder. Dark therapy and treatment as usual has demonstrated efficacy in increasing sleep
duration and reducing manic symptoms among psychiatric inpatients in acute manic episodes
compared to treatment as usual (Barbini et al., 2005; Wehr et al., 1998; Wirz-Justice et al.,
1999). Total restriction of light for extended periods each day, however, is not well-tolerated by
patients and would be impractical for many individuals in the general population (Phelps, 2008),
therefore indicating the need for more tolerable methods of simulating darkness.
One alternative to dark therapy is to block blue wavelength light from reaching a person’s
ipRGCs through the use of amber-tinted glasses. Experimental findings indicate that ambertinted glasses are able to create a state of virtual darkness by sufficiently filtering blue light
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wavelengths from the environment. This virtual darkness state allows melatonin levels to rise
similarly as in a state of actual darkness while also allowing individuals to view the rest of the
visible light spectrum and continue with their nightly activities as usual (Cajochen et al., 2005;
Sasseville et al., 2006). In laboratory studies, virtual darkness prevents the suppression of
melatonin production when participants wear amber-tinted glasses while using blue lightemitting electronic devices prior to bed (Figueiro et al., 2011; Figueiro & Overington, 2015; van
der Lely et al., 2015). In clinical samples of patients with bipolar disorder, virtual darkness has
demonstrated efficacy in improving SOL (Phelps, 2008) and SE (Henriksen et al., 2020), and
decreasing (hypo)manic symptoms and the number of psychiatric medications required for
treatment (Henriksen et al., 2016). In contrast, in one sample of patients with depression and
sleep onset insomnia, virtual darkness did not significantly improve insomnia symptoms
compared to placebo (Esaki et al., 2017). The impact of virtual darkness on insomnia symptoms
when combined with CBT-I treatment has also been examined. Patients treated with virtual
darkness and CBT-I showed significantly increased TST and decreased anxiety compared to
patients who received placebo and CBT-I (Janků et al., 2020). Patients with chronic insomnia
who received virtual darkness intervention reported increased TST, sleep quality, and soundness
of sleep compared to patients who received placebo (Shechter et al., 2018). In a non-clinical
sample, virtual darkness significantly decreased SOL and increased SE when participants wore
amber glasses while viewing blue light emitting electronic devices before bed (Ayaki et al.,
2016). Furthermore, virtual darkness treatment appears to be feasible with high adherence to
treatment protocols and minimal adverse effects (Henriksen et al., 2016; Perez Algorta et al.,
2018). Although virtual darkness has demonstrated promising results in both clinical and nonclinical samples, existing research has consisted of small sample sizes focused on improving
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mood disorder symptoms. Therefore, further investigation is necessary to determine whether
virtual darkness may represent an effective, accessible, and economical intervention to improve
insomnia symptoms generally.
Intra-individual Variability in Sleep Research
Sleep intervention research has traditionally utilized weekly averages of sleep parameters
(e.g., mean TST, mean SOL, mean sleep quality, etc.) to assess for improvements in sleep and
determine the impact of sleep problems on daytime functioning. Comparing mean differences
between treatment groups and within individuals from pre- to post-treatment can be a useful
method for identifying whether an intervention demonstrates efficacy. Use of this method alone,
however, may be problematic because sleep patterns appear to display high intra-individual
variability (IIV, also referred to as "night-to-night variability"; Knutson et al., 2007; van Hilten
et al., 1993). For example, two individuals may each have an average SE of 80% over a period of
four days, but Person 1 and Person 2 could reach the same mean SE from very different sleep
patterns. Person 1 could achieve a mean SE of 80% by sleeping with close to 80% efficiency
each night (e.g., 80% SE on days one through four). In contrast, Person 2 could reach the same
mean SE of 80% through a much more inconsistent sleep pattern (e.g., 100% SE on day one,
60% on day two, 90% on day three, and 70% on day four). In this case, individuals with identical
mean SEs actually have very different sleep patterns. Such within-person variability in sleep
patterns is often greater than mean differences between groups (Dillon et al., 2015; Knutson et
al., 2007; Mezick et al., 2009), and individuals with more inconsistent sleep patterns are more
likely to experience greater daytime functional impairment compared to individuals whose sleep
patterns are more consistent (Becker et al., 2017). Therefore, examining IIV in addition to mean
differences in sleep parameters is critical to evaluating the utility of a sleep intervention.
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Greater IIV among youth has been associated with increased behavioral difficulties.
Specifically, greater IIV of TST and bedtime scheduling is associated with poorer classroom
behavior (Bates et al., 2002). Higher IIV of bedtime and waking schedules have been linked to
attention problems (Vaughn et al., 2015; Yokomaku et al., 2008), aggression, and internalizing
problems (Yokomaku et al., 2008). Higher sleep IIV may also be associated with greater
difficulties with working memory among school-age children, particularly in the first few hours
after waking (Könen et al., 2015). IIV of TST among adolescents is associated with an increased
incidence of risky behavior even after controlling for mean TST (Kuo et al., 2015; McHale et al.,
2011). Sleep IIV has also demonstrated associations with measures of body mass index, obesity,
and undesirable metabolic and nutrition-related outcomes (e.g., higher triglyceride levels) among
youth in some studies but not others (Becker et al., 2017). Adults with higher IIV of TST may be
at greater risk for developing obesity, diabetes, and heart problems (Patel et al., 2014). In
contrast, findings regarding the relationship between sleep IIV and daytime sleepiness in adults
are mixed, with some studies but not others indicating significant relationships between sleep IIV
and daytime fatigue. More variable TST in particular may be associated with lower cognitive
functioning among older but not younger adults (Bei et al., 2016). Variability in bedtime
schedule among university students was also significantly associated with worse subjective sleep
quality (Kang & Chen, 2009). In summary, sleep IIV may increase risk for a host of negative
outcomes among youth and adults.
Although many insomnia interventions have been researched extensively, few studies
have examined the impact of sleep interventions on IIV specifically. Of the few studies that have
examined IIV as an outcome, findings have been mixed (Becker et al., 2017; Bei et al., 2016).
Among youth, one sleep hygiene program for high school students demonstrated efficacy in
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decreasing IIV of bedtime and waking schedules compared to a control group (Sousa et al.,
2007; Sousa et al., 2013). A 9-participant pilot study of a mindfulness-based in-school sleep
intervention for adolescents identified a small decrease in IIV for bedtime and waketime, but did
not assess changes in IIV for any other sleep parameters (Bei et al., 2013). Among adults, CBT-I
has demonstrated improvements in IIV of self-reported TST, WASO, SE, and SOL. Changes in
objectively measured sleep parameters (i.e., actigraphy), however, were not significant, and
CBT-I did not significantly improve IIV of subjective sleep quality (Bei et al., 2016). Inadequate
treatment for all aspects of sleep IIV may be most detrimental for youth and young adults,
because sleep IIV may be particularly pronounced for these age groups compared to middle-aged
and older adults (Bei et al., 2016). Young adults not only have greater sleep IIV compared to
older adults, but they also experience sleep problems at high rates (Buboltz et al., 2001; Lund et
al., 2010; Nadorff et al., 2011; Schlarb et al., 2012; Taylor et al., 2011, 2013). Therefore, it is
important to identify cost-effective and feasible interventions to target insomnia symptoms and
reduce sleep IIV among young adults. The present study aimed to (1) evaluate the feasibility of
virtual darkness treatment, (2) assess whether treatment with virtual darkness reduces IIV of
sleep parameters and mood upon waking, and (3) determine whether sleep IIV is associated with
impairments in daytime functioning in a sample of otherwise healthy young adults with moderate
to severe insomnia.
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Chapter 2: Specific Aims
Aim 1
Sleep is a fundamental biological mechanism that promotes cognitive functioning and
physical and emotional well-being (e.g., Araújo & Almondes, 2014; Brand & Kirov, 2011; Chen
et al., 2006; Rao et al., 2009). However, sleep problems (e.g., insomnia) are common and may
disproportionally impact adolescents and young adults due to biological changes in sleep-wake
cycles that occur during this developmental period (Bruce et al., 2017; Colrain & Baker, 2011;
Crowley et al., 2007). Existing sleep interventions for insomnia can be difficult for patients to
access (Perlis & Smith, 2008; Zachariae et al., 2016), may result in undesirable side effects (Lie
et al., 2015), and demonstrate efficacy in improving some sleep variables but not others (Blake et
al., 2017; Trauer et al., 2015). Therefore, the primary aim of this study was to evaluate whether
treatment with virtual darkness is a feasible and well-tolerated intervention among young adults
with insomnia. Hypotheses for Aim 1 were as follows:
1a. Participants will demonstrate greater than or equal to 80% compliance with wearing
the virtual darkness glasses each night and completing a daily sleep diary.
1b. Side effects of virtual darkness treatment are expected to be consistent with
discomfort associated with wearing any type of glasses (e.g., eye strain, headache,
discomfort where the glasses sit on the nose and ears, etc.). Virtual darkness treatment is
not expected to cause any additional adverse events.
1c. The overall attrition rate for the present study will be approximately 20%, consistent
with the expected attrition rate for clinical trials.
Aim 2
Most prior sleep intervention research has used weekly averages of sleep variables (e.g.,
mean total sleep time each week) to evaluate intervention efficacy and assess the impact of sleep
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problems on daytime functioning. However, sleep appears to display high intra-individual
variability (IIV; Knutson et al., 2007; van Hilten et al., 1993) which may result in lower sleep
quality and more daytime impairment (Becker et al., 2017). Furthermore, sleep IIV may be more
common among younger individuals compared to older adults, and may be particularly
problematic for adolescents and young adults (Bei et al., 2016). Existing studies examining the
impact of existing sleep interventions on IIV have yielded mixed results (Becker et al., 2017; Bei
et al., 2016). Therefore, the second aim of this study was to determine whether treatment with
virtual darkness is associated with (1) improvements in mean sleep parameters and mood upon
waking, and (2) reductions in daily IIV of sleep parameters and mood upon waking. Hypotheses
for Aim 2 were as follows:
2a. Virtual darkness will be associated with an increase in mean TST compared to
placebo.
2b. Virtual darkness will be associated with a decrease in mean SOL compared to
placebo.
2c. Virtual darkness will be associated with an increase in mean SE compared to placebo.
2d. Virtual darkness will be associated with a decrease in mean WASO compared to
placebo.
2e. Virtual darkness will be associated with an increase in mean sleep quality compared
to placebo.
2f. Virtual darkness will be associated with an increase in positive mood upon waking
compared to placebo.
2g. Virtual darkness will be associated with an increase in energy upon waking compared
to placebo.
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2h. Virtual darkness will be associated with an increase in calmness upon waking
compared to placebo.
2i. Participants will demonstrate greater reduction in IIV of TST during the active
treatment phase compared to the placebo phase.
2j. Participants will demonstrate greater reduction in IIV of SOL during the active
treatment phase compared to the placebo phase.
2k. Participants will demonstrate greater reduction in IIV of SE during the active
treatment phase compared to the placebo phase.
2l. Participants will demonstrate greater reduction in IIV of WASO during the active
treatment phase compared to the placebo phase.
2m. Participants will demonstrate greater reduction in IIV of sleep quality during the
active treatment phase compared to the placebo phase.
2n. Participants will demonstrate greater reduction in IIV of mood valence upon waking
during the active treatment phase compared to the placebo phase.
2o. Participants will demonstrate greater reduction in IIV of energy upon waking during
the active treatment phase compared to the placebo phase.
2p. Participants will demonstrate greater reduction in IIV of calmness upon waking
during the active treatment phase compared to the placebo phase.
Aim 3
Individuals who experience greater IIV may demonstrate more behavioral and cognitive
difficulties during waking hours (Becker et al., 2017). Therefore, the third aim of this study was
to determine whether participants with higher weekly sleep IIV demonstrate greater impairment
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in weekly daytime functioning compared to participants with lower weekly sleep IIV across the
study period. Hypotheses for Aim 3 were as follows:
3a. Young adults with greater sleep IIV will experience more daytime negative affect
compared to young adults with lower sleep IIV.
3b. Young adults with greater sleep IIV will experience less daytime positive affect
compared to young adults with lower sleep IIV.
3c. Young adults with greater sleep IIV will exhibit slower mean reaction times on an
attention-based task compared to young adults with lower sleep IIV.
3d. Young adults with greater sleep IIV will exhibit greater variability in reaction times
on an attention-based task compared to young adults with lower sleep IIV.
3e. Young adults with greater sleep IIV will make more omission errors on an attentionbased task compared to young adults with lower sleep IIV.
3f. Young adults with greater sleep IIV will make more commission errors on an
attention-based task compared to young adults with lower sleep IIV.
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Chapter 3: Methods
Participants
Participants were 24 young adults with moderate to severe insomnia symptoms at the
time of study participation. Participants completed an online screening protocol. As part of this
screening, potential participants completed the Pittsburgh Sleep Quality Index (PSQI; Buysse et
al., 1989). Participants with PSQI total scores > 5 were invited to attend a screening visit to
determine eligibility to participate in the present study. To be included in the study, participants
met the following inclusionary criteria: participants were (1) between the ages of 18 and 45; (2)
able and willing to grant informed consent; and (3) experiencing current sleep difficulties as
indicated by a PSQI total score > 5. Exclusionary criteria included: (1) current psychopathology
(e.g., major depressive disorder, generalized anxiety disorder); (2) current substance misuse; (3)
current clinically significant suicidal ideation or risk for suicide; (4) current, serious medical
illness; (5) retinal disease or systematic illness with retinal involvement; (6) current use of a
psychotropic medication with direct effects on melatonin; and (7) pregnancy or lactation.
Measures
Consensus Sleep Diary (CSD). Participants received a text message each morning with
a Qualtrics link to an electronic version of the CSD (Carney et al., 2012). The CSD is a
standardized self-report measure that assesses the previous night’s sleep. The CSD measures the
time at which a participant tried to fall asleep, the time at which the participant initially got into
bed, how long it took to fall asleep, the number of times the participant woke up after initially
falling asleep, how long any awakenings lasted, the time at which the final awakening occurred,
and the participant’s subjective report of their sleep quality.
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CSD responses were used to calculate total sleep time and sleep efficiency, number of
wakings after sleep onset (WASO), sleep onset latency, and subjective experience of sleep
quality and restfulness of sleep. Total sleep time (TST) was calculated as the total sleep episode
minus time spent awake during WASO periods.Sleep efficiency reflected the percentage of time
a participant was asleep compared to how much time they were in bed and was calculated as
TST divided by the total time in bed, multiplied by 100. WASO was derived from the number of
times participants report waking after initial sleep onset. Sleep onset latency was the number of
minutes participants report needing to fall asleep. Subjective sleep quality was rated on a Likert
scale including the following response options: very poor, poor, fair, good, and very good.
Multidimensional Mood Questionnaire (MDMQ). The MDMQ is a 6-item self-report
questionnaire used to measure mood valence, calmness, and energetic arousal. Items are rated on
a Likert scale from zero to six and measure the degree to which participants feel tired versus
awake, content versus discontent, agitated versus calm, full of energy versus without energy,
unwell versus well, and relaxed versus tense. The tired-awake and full of energy-without energy
items comprise the energetic arousal subscale. The content-discontent and unwell-well items
make up the mood valence subscale. The agitated-calm and relaxed-tense items comprise the
calmness subscale. Higher scores on the three subscales indicate greater energy, calmness, and
positive mood valence (the full of energy-without energy, relaxed-tense, and content-discontent
items are reverse coded prior to analysis). The MDMQ demonstrates between-person reliability
greater than .90 for all subscales and within-person reliability greater than .70 for all subscales,
and is sensitive to change over time (Wilhelm & Schoebi, 2007). Participants completed the
MDMQ each morning at the same time they completed the CSD.
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Pittsburgh Sleep Quality Index (PSQI). The PSQI is a widely-used 19-item self-report
measure of sleep quality (Buysse et al., 1989). The PSQI produces seven component scores,
including subjective sleep quality, latency, duration, efficiency and disturbances, as well as use
of sleeping medication and daytime impairment. The PSQI also produces a total score, with
scores greater than five indicating moderate to severe sleep difficulties among college students
(Dietch et al., 2016). The PSQI has yielded internal consistency alphas between .67 and .83
depending on the sample used (e.g., clinical versus non-clinical), and test-retest reliability
coefficients greater than .70 (Mollayeva et al., 2016). Participants completed the PSQI at all
study visits (i.e., baseline, week 1, week 2, week 3, and post-assessment).
Positive and Negative Affect Schedule (PANAS-20). The PANAS-20 is comprised of
two 10-item scales that measure positive and negative affect. Items are rated from one (“very
slightly or not at all”) to five (“extremely”) and a sum score is calculated for each scale (Watson
et al., 1988). The PANAS-20 demonstrates good internal consistency (alphas > .81) (Villodas et
al., 2011; Watson et al., 1988) and yields test-retest reliability coefficients between .39 and .71
(Watson et al., 1988). Participants completed the PANAS-20 at all study visits as a measure of
positive and negative affect over the past week of treatment.
Psychomotor Vigilance Task (PVT). The PVT is a computerized measure of sustained
attention (Dinges & Powell, 1985). The PVT measures a participant’s reaction time to the
presence of a stimulus presented at variable times. The stimulus is a clock starting at zero
counting up in milliseconds. The stimulus is presented randomly every 2-10 seconds for 10
minutes. Participants are instructed to respond to the presence of the stimulus as quickly as
possible by pushing a button. The PVT provides scores for the (1) mean response time for
correct trials, (2) standard deviation of within-person response time for correct trials as a
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measure of variability, (3) total number of lapses in attention (i.e., omission errors defined as
>500ms response time), and (4) total number of false responses (i.e., commission errors) (Dinges
& Powell, 1985; Sforza et al., 2004). The PVT demonstrates acceptable test-retest reliability,
involves only minor learning effects compared to other vigilance tasks, and is sensitive to
changes in sleep deprivation and daytime sleepiness (Dorrian et al., 2005). Participants
completed the PVT at all study visits.
Modified Demographics Section of the Diagnostic Interview for Genetic Studies,
Version 4.0/BP (DIGS 4.0/BP). A modified version of the Demographics Section of the DIGS
4.0/BP (National Institute of Mental Health Molecular Genetics Initiative, 2004) was used during
the baseline visit to record participants’ demographic information and screen for exclusionary
medical conditions. The DIGS 4.0/BP Demographics Section includes questions regarding age,
gender, race, ethnicity, citizenship, religious affiliation, marital status, military status, number of
children, living arrangements (e.g., alone or with others), occupation, years of schooling, height
and weight, medical history, current medications, developmental milestones, and pregnancy
history. Questions were added to the DIGS 4.0/BP Demographics Section to assess for: (1)
systematic illnesses with retinal involvement (e.g., macular degeneration), and (2) current sleep
medications (e.g., melatonin, zolpidem, etc.).
MINI International Neuropsychiatric Interview, Version 7.0.2 for DSM-5 (M.I.N.I.).
The M.I.N.I. (Sheehan et al., 1998) was used to assess for current psychopathology. The M.I.N.I.
is a structured interview that uses Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition (American Psychiatric Association, 2013) criteria to assess for major depressive
disorder, suicidality, bipolar disorders, anxiety disorders, obsessive-compulsive disorder,
posttraumatic stress disorder, alcohol and substance use disorders, psychotic disorders, eating
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disorders, and antisocial personality disorder. The M.I.N.I. demonstrates acceptable to excellent
interrater reliabilities for all diagnostic categories (kappa values .75-1.00). The M.I.N.I. yields
kappa values between .35 and 1.00 for test-retest reliability depending on diagnostic category
(Sheehan et al., 1998). The M.I.N.I. also includes rating scales that allow participants to (1) rate
the severity of symptoms that cut across disorders (e.g., sleep problems, anger, memory
problems), and (2) rate the severity of impairment in functioning caused by current symptoms.
Participants used the second rating scale to rate the severity of functional impairment caused by
current sleep problems.
Adverse Event (AE) Interview. Study staff recorded adverse events experienced by
participants at each weekly visit using the AE interview. The AE interview assessed whether
participants experienced any of the following over the previous week: eye strain, dry eyes,
blurred vision, headache/head pain/head pressure, morning grogginess, daytime sleepiness,
vertigo, irritability, stomach pain, or vivid dreams. Participants were also asked whether they
skipped a social event in the past week as a result of having to wear the study glasses each
evening.
Procedures
Baseline Visit. Figure 1 displays the study procedures. Participants who screened above
the PSQI threshold were contacted by study staff. Potential participants who agreed to participate
in the baseline visit were then scheduled to complete a baseline visit with study staff, which
lasted approximately three hours. Participants were provided with a written informed consent
document that described the potential benefits and risks of study participation. Study staff also
verbally reviewed the informed consent form with participants. Participants were provided with
an ample amount of time to ask questions and consider participation. Participants who consented
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to the study were assessed by trained clinical psychology doctoral students with the following
measures: (1) modified Demographics Section of the DIGS 4.0/BP (National Institute of Mental
Health Molecular Genetics Initiative, 2004); (2) M.I.N.I. (Sheehan et al., 1998); and (3) AE
interview of potential AEs experienced in the week prior to the baseline visit (e.g., dry eyes, eye
strain, headaches). Participants also completed the PANAS-20 (Watson et al., 1988), PSQI
(Buysse et al., 1989), and PVT (Dinges & Powell, 1985).
Intervention Conditions and Randomization. Active study treatment consisted of
participants wearing either the Uvex S1933X Skyper eyewear with amber lenses or the Uvex
S0360X Ultra-spec 2000 eyewear with amber tinting. Participants who did not wear eyeglasses
were given the Skyper eyewear and individuals who did wear eyeglasses were given the Ultraspec Eyewear. The amber tinting of these lens consistently blocks more than 70% of blue
wavelength light (<500 nm) while permitting 70% of available nighttime light to pass. The
blocking of the blue wavelength light creates “virtual darkness.” Placebo treatment consisted of
participants wearing either the Uvex S1905 Skyper eyewear with clear lenses or the Uvex
S0250X Ultra-spec 2000 eyewear with clear tinting. These glasses permit nearly all available
nighttime light to pass and do not block blue wavelength light.
The study used a randomized, multiple baseline, double-blind crossover design. At the
end of the screening visit, eligible participants were block randomized to one of three treatment
conditions. The multiple-baseline, crossover treatment conditions were:
I.

One week of placebo, crossover to three weeks of virtual darkness treatment

II.

Two weeks of placebo, crossover to two weeks of virtual darkness treatment

III.

Three weeks of placebo, crossover to one week of virtual darkness treatment
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Blinding Procedures. This study was a double-blind trial in which neither the assessor
nor the participant were aware of the study treatment condition. To maintain blinding, research
assistants provided the intervention glasses in opaque paper marked with participant IDs and
week numbers. A separate research assistant, not involved in participant screening, packaged and
labeled all intervention glasses when other research participants were not present. At the study
visits, the assessor provided the participant with the correct sealed, wrapped glasses package and
instructed the participant in how to use the glasses.
All study participants, regardless of randomization order, were instructed to wear their
glasses for two to three hours each night prior to their desired bedtime. For example, if a
participant typically fell asleep at 1:00am, then the participant was encouraged to start wearing
their glasses at 10:00pm.
Daily Tasks. Participants completed the CSD (Carney et al., 2012) and MDMQ
(Wilhelm & Schoebi, 2007) each morning. Participants also received nightly text messages
approximately 2 hours prior to their reported bedtime that (1) reminded the participant to wear
their glasses, and (2) asked the participant to take a “selfie” with their glasses on and text the
picture back. The selfie was a measure to both check and increase study treatment compliance.
Weekly Visits. Participants returned approximately every seven days for the duration of
the randomized portion of the study. Weekly visits were approximately 20 minutes and included
the following procedures. Participants were provided with a new, wrapped pair of glasses for the
week. Participants completed the PANAS-20 (Watson et al., 1988), PSQI (Buysse et al., 1989),
and PVT (Dinges & Powell, 1985) regarding the prior week. Participants also completed the AE
interview to record AEs that occurred during the prior week.
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Post-Assessment Visit. At the end of week four, participants completed the posttreatment assessment visit. This visit lasted approximately 1.5 hours and consisted of the initial
baseline visit measures, including the AE interview, PANAS-20 (Watson et al., 1988), PSQI
(Buysse et al., 1989), and PVT (Dinges & Powell, 1985).
Compensation. Participants were provided cash compensation at each of the weekly
visits and at the post-assessment visit. All participants were compensated a minimum of $2 and
a maximum of $5 for attending each of the weekly visits. Participants received $2 for attending
each 15-minute weekly visit and received additional compensation based on completion of the
daily study procedures as follows:
% of Daily Procedures
Completed
> 80%
70% to 79%
60% to 69%
< 60%

Additional
Compensation
$3
$2
$1
$0

Participants received $50 after completing the post-assessment visit. The post-assessment
visit compensation was greater than the amount provided at each weekly visit in order to be
commensurate with the longer length of the post-assessment visit. Compensation was not
provided at the intake screening visit.
Statistical Analyses
Aim 1: Evaluate whether treatment with virtual darkness is a feasible and welltolerated intervention among young adults with insomnia. Compliance with the study
protocol was assessed by quantifying the percentage of daily selfie checks and CSD
questionnaires that participants completed across the study period, with greater than or equal to
80% compliance indicating adequate adherence to study procedures. A composite of participant
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adverse effect profiles was compiled and includes the adverse experienced by participants in
each side effect category (e.g., eye strain, headaches) for the baseline, placebo, and virtual
darkness phases. Attrition was calculated as the percentage of enrolled participants who did not
complete the post-assessment visit.
Aim 2: Determine whether treatment with virtual darkness is associated with
reductions in IIV of sleep parameters and mood upon waking. Most prior sleep IIV research
has used individual standard deviations (ISD), mean square of successive differences (MSSD),
coefficients of variance, and interquartile range to quantify IIV for various sleep parameters (Bei
et al., 2016). These methods are useful in assessing a person’s mean IIV over a period of time;
however, they provide information about mean variability, but not day-to-day variability.
Therefore, a multilevel modeling (MLM) framework was used to assess changes in daily sleep
parameters following virtual darkness intervention. Specifically, MLM was used to predict daily
sleep variability from treatment phase over time. Growth modeling (i.e., longitudinal MLM;
Raudenbush & Bryk, 2002) is a preferred method of analysis for within-subject longitudinal data
because it (1) accounts for clustering of data within individuals and between groups, and (2) is
more robust to missing values than other methods (Tabachnick & Fidell, 2007). Despite
procedures to reduce the presence of missing data (e.g., differential compensation), missing data
was present due to the intensive sampling frame and by design (i.e., responses at different times).
Level 1 of a hierarchical growth model is the within-cluster or within-person
measurements. Treatment phase is a level 1 within participant variable. Level 2 of a hierarchical
growth model is the between-cluster or -person measurements. Using TST as the example
dependent variable, a series of MLM would be fit as follows:
I.

Intercept-only model (i.e., unconditional growth model).
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Level 1
ܶܵܶ௧ ൌ ߚ  ݎ௧
Level 2
ߚ ൌ ߛ  ߤ
Mixed Model
ܶܵܶ௧ ൌ ߛ  ݎ௧  ߤ
In this equation, TSTti represents TST at timepoint t from treatment phase i. The rate is
equal to the grand mean (ߛ ሻ plus within treatment phase (i.e., within placebo and within active
treatment) variation in TST over time (ݎ௧ ሻ and between treatment phase (i.e., between placebo
and active treatment) variation (ߤ ሻ.
II.

Treatment x Time Effect

An interaction term can be added to level 1 of the model to determine whether TST
varies as a function of the number of days a participant spends in the active treatment phase.
Level 1
ܶܵܶ௧ ൌ ߚ  ݎ௧   ߚଵ ܻܣܦ௧ ൈ ݎ௧
Level 2
ߚ ൌ ߛ  ߤ
ߚଵ ൌ ߛଵ  ߤଵ
Mixed Model
ܶܵܶ௧ ൌ ߛ  ݎ௧  ߤ ߛଵ ܻܣܦ௧ ൈ ݎ௧
The model will now provide level 1 estimates for the main effect of treatment phase in
addition to the interaction between day and treatment phase. A significant interaction effect will
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indicate that TST varies based on how many days a participant has spent in the active treatment
phase.
III.

MELSM

Although the previously described model would provide information about changes in
sleep parameters within treatment phase over time, traditional MLM operates under the
assumption that all participants have an equal amount of variability in the constructs measured.
Given the substantial differences observed in sleep patterns within and between individuals, it is
likely that the assumption of equivalence of intra-individual variability between participants
cannot be made when applied to analyses of sleep parameters in particular (Shaffer et al., 2020).
Therefore, the present study used mixed-effects location-scale modeling (MELSM), an advanced
type of MLM specifically designed to measure IIV of dependent variables (Shaffer et al., 2020),
to assess the relationship between treatment with virtual darkness and changes in the means and
IIV of sleep parameters.
MELSM is an extended random-intercept model which provides the same information as
traditional MLM approaches, but also allows within- and between-subjects variances to be
affected by each independent variable instead of being treated as homogenous across subjects
and groups (Hedeker & Nordgren, 2013). In other words, MELSM allows independent variables
(i.e., treatment phase) to influence within-subjects variance (IIV) in addition to mean levels to
assess whether the means and IIV of sleep parameters change as levels of the independent
variables increase or decrease (Shaffer et al., 2020). In MELSM, level 1 predictors include the
within-subject independent variables. Level 1 predictors in the MELSM models included
treatment phase (placebo vs. active) and an interaction term of treatment phase x day to assess
whether sleep parameters changed as the time spent in active treatment increased. Level 2
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predictors in MELSM indicate the random subject effect (i.e., each subject’s influence on their
own level 1 data points). Independent variables are then allowed to influence within- and
between-subjects variances by using log-linear representations. Dependent variables included
TST, SOL, SE, WASO, and sleep quality obtained from daily CSD (Carney et al., 2012)
responses. Additional dependent variables included participants’ self-reported mood upon
waking from the three subscales (mood valence, energy, and calmness) of the MDMQ completed
by participants each morning (Wilhelm & Schoebi, 2007). Separate mixed-effects location-scale
models were performed for each dependent variable.
MELSM was conducted via the MIXREGLS program as described by Hedeker and
Nordgren (2013). The MIXREGLS program is now contained within the broader MixWILD
program (Dzubur et al., 2020) and uses maximum likelihood to complete analyses in three
stages. All stages use a random intercept model to determine main effects of independent
variables. In stage 1, the main effects and between-subjects variance are calculated. In stage 2,
both within- and between-subjects variances are calculated in addition to main effects. In stage 3,
main effects, within- and between-subjects variances, and random scale and location effects are
calculated. Likelihood ratio tests are used to evaluate statistical significance between model
stages (Hedeker & Nordgren, 2013). Within-subjects variance represents participants’ IIV for
each sleep parameter. Random scale effects indicate how much a participant’s scores vary
around their linear trajectory over time. Random location effects indicate how much a
participant’s scores are different from the mean. Estimates for the main effects are calculated as
beta values. Log-linear estimates are provided for the between- and within-subjects variance
effects. Log-linear estimates can then be exponentiated to provide standard deviation ratios
indicating the ratio of within-subject standard deviations that occurs as levels of each predictor
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change. For example, a standard deviation ratio that is greater than one indicates that as a
predictor increases, variability also increases. Per Hedeker and Nordgren (2013), the mixed
effects model can be visualized using a matrix. The following is an example equation with four
days of data for participant i and TST as the dependent variable:
ߝ
ͳ   ݁ݏ݄ܽ  ݁ݏ݄ܽ ൈ ݀ܽݕ ߚ
ߠଵ
ܶܵܶ
ߝଵ
ͳ  ݁ݏ݄ܽ  ݁ݏ݄ܽ ൈ ݀ܽݕଵ ߚଵ
ߠଵ
ܶܵܶଵ
൦
൪ൌ൦
൪൦ ൪    ൦ ൪ൣߪజ ൧    ൦ߝ ൪
ܶܵܶଶ
ߠଵ
ͳ  ݁ݏ݄ܽ  ݁ݏ݄ܽ ൈ ݀ܽݕଶ ߚଶ
ଶ
ߝ
ܶܵܶଷ
ߠଵ
ͳ  ݁ݏ݄ܽ  ݁ݏ݄ܽ ൈ ݀ܽݕଷ ߚଷ
ଷ
This formula includes a random subject intercept, level 1 predictors (treatment phase and
interaction between treatment phase and day), standardized random effects (ߠଵ ), standard
deviation (ߪజ ), and error (ߝ ). Variance is then modeled as:
I. Between-subjects:
ଶ
ߪజ
ൌ ሺߙ   ߙଵ ݁ݏ݄ܽ ሻ,

where ߙଵ represents the difference in between-subjects variance between treatment
phases.
II. Within-subjects:
ଶ
ൌ ሺ߬  ߬ଵ ݁ݏ݄ܽ   ߬ ߠଵ   ߪఠ ߠଶ ሻ,
ߪఌ

where ߬ଵ ݁ݏ݄ܽ represents the change in within-subjects variance between treatment
phases, ߬ ߠଵ represents the random location effect on a participant’s within-subjects variance,
and ߪఠ ߠଶ represents the standard deviation of the random scale effect. Models provide
information regarding whether within-subjects variance (i.e., intra-individual variability) changes
as a function of independent variables.
Aim 3: Determine whether participants with higher sleep IIV demonstrate greater
impairment in daytime functioning compared to participants with lower sleep IIV across
the study period. Positive and negative affect were quantified using the sum scores for the
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PANAS-20 positive and negative affect subscales (Watson et al., 1988). Attention was assessed
using the PVT (Dinges & Powell, 1985) mean response time, standard deviation of response
time, omission errors, and commission errors. The PANAS-20 and PVT were collected at the
baseline, weekly, and post-assessment visits for a total of five timepoints per participant.
Two methods were used to calculate weekly sleep IIV: (1) mean square of successive
differences (MSSD) and (2) individual standard deviation (ISD). The MSSD and ISD are
commonly used to quantify sleep IIV when using IIV as an independent variable to predict
outcomes (Becker et al., 2017; Bei et al., 2016). The MSSD was calculated as the average of the
squared differences between consecutive measurement points (Jahng et al., 2008). Using TST as
an example, the square of successive difference between two nights was calculated as:
(TST of night 2 – TST of night 1)2.
The square of successive differences was calculated between each night of sleep and then
averaged to create a mean square of successive differences score for each week. For example, the
MSSD for TST during Week 1 was calculated as follows:
[(TST of night 2 – TST of night 1)2 + (TST of night 3 – TST of night 2)2 + (TST of night
4 – TST of night 3)2 + (TST of night 5 – TST of night 4)2 + (TST of night 6 – TST of
night 5)2 + (TST of night 7 – TST of night 6)2] ÷ 7.
This process was then be repeated for Weeks 2 through 4 and for all sleep parameters. This
resulted in four weekly MSSD values for each participant for TST, SOL, SE, WASO, and sleep
quality.
The ISD represents the mean standard deviation of each sleep parameter for each
participant each week. For example, the ISD of TST for Week 1 was calculated as the standard
deviation of TST for that week. This resulted in four ISD values per participant for each sleep
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parameter (e.g., ISD of TST for Week 1, ISD of TST for Week 2, ISD of TST for Week 3, and
ISD of TST for Week 4), similar to the MSSD.
Multilevel modeling was used to predict weekly daytime functioning from weekly sleep
IIV scores. MLMs were conducted via the R statistical software platform (R Core Team, 2013)
and were fit for each sleep IIV parameter and outcome variable. Level 1 of each model included
IIV of the weekly sleep parameter at week 1, week 2, week 3, and post-assessment. Level 2 of
each model included baseline daytime functioning scores as a control variable. Dependent
variables included baseline daytime functioning scores at week 1, week 2, week 3, and postassessment. For example, weekly MSSD of TST was used to predict weekly positive affect
scores while controlling for baseline positive affect scores. Then, weekly ISD of TST was used
to predict weekly positive affect scores while controlling for baseline positive affect scores.
These models were repeated for the MSSD and ISD of all other sleep parameters and all other
outcome variables.
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Chapter 4: Results
Table 1 displays demographic and baseline characteristics of the overall sample.
Participants were a mean age of 20.08 years and 96% (n = 23) of the sample were women.
Twenty-nine percent of the sample (n = 7) identified as Asian American/Pacific Islander, 29% (n
= 7) as Caucasian, 17% (n = 4) as African American, 4% (n = 1) as American Indian/Alaskan
Native, and 21% (n = 5) as another race or biracial. Forty-two percent of participants (n = 10)
identified as Hispanic or Latino.
Aim 1. Feasibility of Virtual Darkness Treatment
Hypothesis 1a: Compliance. Overall, participants completed an average of 90% of the
nightly selfie checks used to monitor compliance with wearing study glasses each evening. On
average, participants completed 83% of daily sleep diaries. Four participants demonstrated less
than 80% compliance with nightly selfie checks (57-77% compliance rates), and six participants
demonstrated less than 80% compliance with completing daily sleep diaries (43-77% compliance
rates). Of the participants with less than 80% compliance, only two participants demonstrated
low compliance with both the selfie checks and sleep diaries. MELSM models were conducted
with and without these two participants to determine whether low compliance from these two
participants meaningfully impacted results. Patterns of results did not change substantially
following removal of these two participants, and all participants are included in the final
MELSM results.
Hypothesis 1b: Adverse Events. Table 2 displays the number and percentage of
participants who reported adverse events (AEs) in each phase of the study. Participants reported
AEs at baseline, during the placebo phase, and during active treatment. The most common AEs
across treatment phase were daytime sleepiness, morning grogginess, and vivid dreams.
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Percentages of participants reporting AEs were either consistent across treatment phase or
appeared to slightly decrease across phases (e.g. headache). There was no attrition related to AEs
during the study period. In summary, virtual darkness does not appear to produce meaningful
side effects that would preclude its use.
Hypothesis 1c: Attrition. Five of the 24 enrolled participants (20.83%) discontinued
study participation prior to completing the study protocol. All five participants discontinued
study participation during the placebo phase. Reasons for discontinuation included: (1) lack of
time available to complete the study procedures (n = 2), (2) feeling as though the study
procedures were too tedious (n = 1), and (3) wishing to find a different study to participate in to
obtain research participation credits for a psychology course rather than cash compensation (n =
1). A fifth participant was completing week three of the study when a state of emergency related
to the COVID-19 public health crisis was issued in Nevada. This participant elected to
discontinue study participation due to COVID-related safety concerns about traveling to the
UNLV campus for remaining study visits.
Aim 2. Impact of Virtual Darkness on IIV of Sleep Parameters
Table 3 displays the grand means and standard deviations of sleep parameters and mood
upon waking during the placebo and virtual darkness phases. Table 4 displays an overview of
significant findings from MELSM analyses. Table 5 displays the MELSM results assessing the
impact of virtual darkness treatment on the mean and IIV of sleep parameters. Table 6 displays
the MELSM results assessing the impact of virtual darkness treatment on the mean and IIV of
mood valence, energy, and calmness upon waking. Figures 2 through 9 display weekly means
and standard deviations for each outcome variable by treatment group.
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Hypotheses 2a and 2i: Total Sleep Time. Virtual darkness was hypothesized to increase
the mean of TST and decrease IIV of TST relative to placebo. In contrast to hypotheses, there
were no significant differences in the mean or IIV of TST between the placebo and virtual
darkness phases indicating that virtual darkness did not improve the mean or IIV of TST. There
was a significant random scale effect for TST indicating that participants differed from each
other in their degree of IIV of TST (i.e., some participants had more variability in TST than
others). There was also a trend toward a random location effect such that participants with higher
mean TST values had less within-subject variability of TST compared to participants with lower
mean TST values (p = .054).
Hypotheses 2b and 2j: Sleep Onset Latency. Virtual darkness was hypothesized to
reduce both the mean and IIV of SOL relative to placebo. There was a significant effect of
treatment phase on mean SOL such that, on average, participants spent approximately seven
minutes less trying to fall asleep during the virtual darkness phase compared to placebo.
Additionally, variability of SOL decreased by approximately 47% during virtual darkness
treatment compared to placebo, IIV ratio = .53 [95% CI = .33 - .86]. Finally, significant random
scale and location effects indicated that (1) some participants had greater variability in SOL than
others, and (2) participants with higher mean SOL had greater within-subject variability in SOL
compared to participants with lower mean SOL. In summary, participants fell asleep faster and
more consistently during the virtual darkness phase compared to placebo.
Hypotheses 2c and 2k: Sleep Efficiency. Virtual darkness was hypothesized to increase
mean SE and decrease IIV of SE relative to placebo. However, there were no significant
differences in the mean or IIV of SE between the placebo and virtual darkness phases, indicating
that virtual darkness did not improve the mean or IIV of SE. There were significant random scale
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and location effects indicating that (1) some participants had greater variability in SE than others,
and (2) participants with higher mean SE had less within-subject variability in SE compared to
participants with lower mean SE.
Hypotheses 2d and 2l: Number of Wakings After Sleep Onset. Virtual darkness was
hypothesized to decrease both the mean and IIV of WASO relative to placebo. There was a
significant effect of treatment phase on mean WASO, such that participants had fewer nighttime
awakenings on average during the virtual darkness phase compared to placebo. There was no
significant effect of virtual darkness on IIV of WASO. There were significant random scale and
location effects indicating that (1) some participants had greater variability in WASO than
others, and (2) participants with higher mean WASO had more within-subject variability in
WASO compared to participants with lower mean WASO. In summary, virtual darkness
decreased mean WASO but did not decrease IIV of WASO compared to placebo.
Hypotheses 2e and 2m: Sleep Quality. Virtual darkness was hypothesized to increase
mean sleep quality and decrease IIV of sleep quality relative to placebo. There was a significant
effect of treatment phase on mean sleep quality, such that participants reported higher sleep
quality on average during the virtual darkness phase compared to the placebo phase. There was
no significant effect of virtual darkness on IIV of sleep quality. There was a significant random
scale effect indicating that some participants had greater variability in sleep quality than others
throughout the study. In summary, virtual darkness increased mean sleep quality but did not
significantly decrease IIV of sleep quality compared to placebo.
Hypotheses 2f, 2g, 2n, and 2o: Mood Valence and Calmness Upon Waking. Virtual
darkness was hypothesized to increase mean positive mood valence and calmness upon waking
and decrease IIV of mood valence and calmness upon waking relative to placebo. There was a
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significant effect of treatment phase on mean mood valence and calmness, such that participants
reported more positive mood upon waking and more calmness upon waking during the virtual
darkness phase compared to the placebo phase. There was no significant effect of virtual
darkness on IIV of mood valence or calmness upon waking. There were significant random scale
effects indicating that some participants had greater variability in mood valence and in calmness
upon waking than others throughout the study. In summary, virtual darkness increased mean
positive mood valence and calmness upon waking but did not significantly decrease IIV of mood
valence or calmness relative to placebo.
Hypotheses 2h and 2p: Energy Upon Waking. Virtual darkness was hypothesized to
increase mean energy upon waking and decrease IIV of sleep quality relative to placebo.
However, there were no significant differences in the mean or IIV of energy upon waking
between the placebo and virtual darkness phases. There was a significant random scale effect
indicating that some participants had greater variability in energy upon waking throughout the
study than others.
Aim 3. Impact of Weekly IIV on Daytime Functioning
Hypotheses 3a through 3f. Hypotheses predicted that, compared to participants with low
weekly sleep IIV, participants with higher weekly sleep IIV would report more daytime negative
affect and less daytime positive affect and would perform worse on a psychomotor vigilance task
(PVT) as evidenced by (1) more commission errors, (2) more omission errors, (3) higher mean
response times, and (4) greater variability in response times.
In contrast to hypotheses, individual standard deviations of TST, SE, SOL, WASO, and
sleep quality were not significantly associated with negative affect, positive affect, PVT
commission errors, PVT mean response times, or standard deviation of PVT response times, all
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ps > .18. However, there was a trend toward a significant association between the individual
standard deviations of TST and PVT omission errors, such that participants with greater IIV of
TST demonstrated more omission errors on the PVT after controlling for baseline PVT omission
error rates, ߚ = .15, p = .06. Mean squares of successive differences of TST, SE, SOL, WASO,
and sleep quality were not significantly associated with negative affect, positive affect, PVT
commission errors, PVT omission errors, PVT mean response times, or standard deviation of
PVT response times, all ps > .08. In summary, greater variability in weekly sleep parameters was
not significantly associated with daytime affect or performance on an attention-based task.
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Chapter 5: Discussion
Insomnia is common among youth and adults (Buboltz et al., 2001; Centers for Disease
Control and Prevention, 2011; Kann et al., 2014; Lund et al., 2010) and results in a variety of
adverse health outcomes (Harvey et al., 2011; Zelinski et al., 2014) and deficits in daytime
functioning (e.g., Alapin et al., 2000; Fortier-Brochu et al., 2012; Gaultney, 2010). Although
current pharmacological and behavioral interventions for insomnia exist, they are often difficult
to access (Perlis & Smith, 2008; Zachariae et al., 2016) and/or result in undesirable adverse
effects (Sateia et al., 2017). As such, this study aimed to assess whether virtual darkness, a novel
intervention, may be a feasible and effective treatment option to improve insomnia among young
adults. Participants demonstrated good adherence to study procedures and reported
improvements in sleep onset latency, number of wakings after sleep onset, sleep quality, positive
mood, and calmness upon waking with virtual darkness treatment compared to placebo. Virtual
darkness treatment did not produce significant improvements in total sleep time, sleep efficiency,
or energy upon waking. In summary, treatment with virtual darkness was feasible and efficacious
in improving some sleep parameters, but not all.
Virtual darkness was a feasible intervention with participants wearing the study glasses
during 90% of evenings enrolled in the study. Virtual darkness was also a tolerable intervention
with regard to adverse events. This is important because current pharmacological interventions
for insomnia often produce undesirable adverse effects which may not be tolerable for many
individuals (Dang et al., 2010; Lie et al., 2015). In contrast, participants in our sample did not
report any adverse events specific to virtual darkness, and rates of adverse events reported at
baseline remained stable or decreased across the placebo and virtual darkness phases. Although
there is a paucity of research related to virtual darkness, our findings are consistent with the few
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existing studies using blue-light blocking glasses to improve dysregulated sleep. Virtual darkness
previously demonstrated good feasibility in randomized controlled trials with small non-clinical
(Burkhart & Phelps, 2009; Perez Algorta et al., 2018; Shechter et al., 2018) and clinical samples
(Henriksen et al., 2016; Henriksen et al., 2020). Additionally, approximately 80% (n = 19) of
participants in our sample completed the four-week treatment protocol which is consistent with
attrition rates in existing clinical trials (e.g., Crutzen et al., 2015; Fabricatore et al., 2009; Leon et
al., 2006; White et al., 2010). Overall, virtual darkness appears to be a feasible and tolerable
intervention among young adults with insomnia.
Treatment with virtual darkness significantly decreased mean SOL and WASO such that
participants fell asleep about seven minutes faster and woke less after initial sleep onset
compared to placebo. Mean sleep quality, positive mood valence upon waking, and calmness
upon waking also improved during the virtual darkness phase compared to placebo. Findings
appear consistent with previous studies of virtual darkness. In one sample of university students,
participants reported fewer nighttime awakenings while wearing amber lenses compared to blue
lenses, though these differences were not statistically significant (Perez Algorta et al., 2018). In
another non-clinical sample of adults, participants wearing virtual darkness glasses had a
significantly greater increase in sleep quality and positive daytime affect over three weeks of
treatment compared to placebo (Burkhart & Phelps, 2009). In a clinical sample of patients
hospitalized during acute manic episodes, patients who wore virtual darkness glasses reported a
significant decrease in manic symptoms and WASO compared to placebo (Henriksen et al.,
2020). In comparison to virtual darkness, recent meta-analytic work indicates that CBT-I appears
to improve SOL by 19 minutes and decrease time spent awake after initial sleep onset by 26
minutes on average (Trauer et al., 2015). Although CBT-I has demonstrated larger improvements
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in some sleep parameters (e.g., SOL) compared to virtual darkness, a full course of CBT-I
typically requires four to ten weeks (Dautovich et al., 2010; Smith et al., 2002). In our sample,
virtual darkness produced improvements in SOL, WASO, sleep quality, and mood during a
shorter treatment period of only one to three weeks. Virtual darkness may therefore represent a
brief intervention option for individuals who are unable to access CBT-I or other behavioral
sleep interventions.
Virtual darkness did not significantly improve mean TST, SE, or energy upon waking in
this sample. Virtual darkness has previously improved TST in some trials (Shechter et al., 2018)
but not others (Henriksen et al., 2020; Perez Algorta et al., 2018). In a clinical sample of
psychiatric inpatients with acute manic symptoms, virtual darkness significantly increased SE by
almost 10% (Henriksen et al., 2020). In comparison, CBT-I appears to produce only mild nonsignificant increases in TST of approximately eight minutes on average, and produces increases
in SE of almost 10% (Trauer et al., 2015), similar to prior virtual darkness findings. Although
improvements were not seen in TST, SE, or energy in our sample, this may be due to the severity
of symptoms reported by participants. Despite reporting poor sleep at baseline (i.e., average
baseline PSQI score of 10.42), participants’ diary-reported sleep symptoms were less severe
compared to the typical baseline severity observed in insomnia intervention studies. For
example, participants in CBT-I trials report pre-treatment SOL of 57.6 minutes, TST of 5.7
hours, and SE of 71.8% on average (Trauer et al., 2015). In contrast, participants in our sample
reported average SOL of 25.2 minutes, TST of 7.4 hours, and SE of 84.3% prior to virtual
darkness treatment. Despite symptoms being less severe in the present sample, virtual darkness
still produced notable improvements in some sleep parameters. Virtual darkness may represent a
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useful alternative treatment option for insomnia given its feasibility and ability to improve
several aspects of sleep disturbance across a brief treatment period.
One innovative aspect of the current study was the examination of intraindividual
variability (IIV) of sleep based on observations that greater IIV may be associated with greater
deficits in daytime functioning (Becker et al., 2017), behavioral difficulties among youth (Bates
et al., 2002; Vaughn et al., 2015; Yokomaku et al., 2008), and risk for physical health problems
(Becker et al., 2017; Patel et al., 2014). Despite the potential importance of high IIV of sleep on
functional outcomes (Knutson et al., 2007) most existing research only evaluates changes in
mean levels of sleep parameters. Prior findings regarding the impact of sleep interventions on
IIV are limited and inconsistent. Some intervention studies have produced decreases in various
aspects of sleep IIV when IIV is quantified using self-report measures (Bei et al., 2013, 2016;
Sousa et al., 2007, 2013). In contrast, sleep intervention studies have not demonstrated a
decrease in sleep IIV when sleep parameters are measured objectively using actigraphy (Bei et
al., 2016). No prior studies have examined whether virtual darkness may be an efficacious
intervention to improve sleep IIV. In the present sample, virtual darkness did not significantly
reduce IIV for most sleep and mood variables, consistent with the existing intervention literature
which has demonstrated only mild or inconsistent effects on IIV that vary by treatment modality
and methods used to quantify sleep parameters and variability. However, virtual darkness did
significantly reduce IIV of SOL. Specifically, participants’ SOL was 47% more consistent on
average during virtual darkness treatment compared to placebo. This is important because
inability to quickly fall asleep may be associated with increased sleep-related worrying before
bed (Heath et al., 2018). Increasing consistency in sleep onset may provide some relief for
individuals who struggle with this aspect of sleep disturbance. The current findings represent a

42

significant contribution to the sleep intervention literature and indicate that virtual darkness may
increase consistency of sleep onset.
In addition to evaluating the efficacy of virtual darkness as a novel intervention, the
present study also aimed to assess whether participants’ weekly IIV of sleep parameters was
associated with daytime functioning outcomes assessed at weekly study visits. Surprisingly,
results were not consistent with prior findings linking greater IIV to daytime functional
impairment (e.g., Becker et al., 2017). Specifically, participants with greater weekly sleep IIV
did not perform significantly worse on the PVT when compared to participants with less IIV,
despite demonstrating poor PVT performance consistent with other samples of adults and
adolescents with sleep disturbance (e.g., Altena et al., 2008; Banks & Dinges, 2007; Beijamini et
al., 2008; Thomann et al., 2014). In addition, weekly sleep IIV was not significantly associated
with positive and negative affect as measured by the PANAS-20. Positive and negative affect
scores were consistent with prior scores derived from healthy young adults (Franzen et al.,
2008), but when compared to scores from university students with poor sleep (M = 19.1; Latif et
al., 2019), participants in our sample reported experiencing less negative affect (M = 14.8) which
may have impacted results. It is also possible that variability in our sample differed from prior
samples in some way (i.e., either more or less variability) and that this may have resulted in
findings that were inconsistent with prior research, though this is difficult to determine given the
wide range of methods used to calculate and report IIV in the existing literature.
Limitations
While this study provides evidence to suggest that virtual darkness may improve
symptoms of insomnia among young adults, there are several limitations that should be
addressed in future controlled trials. First, this study included a small sample size of 24
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participants (19 completers). The small overall sample size did not allow for comparison of
virtual darkness efficacy by treatment duration or demographic variables. However, a moderate
amount of within-subject data was available for analysis with an average of 22.79 sleep diaries
collected per participant. MELSM was also used as a more robust within-subjects test of efficacy
compared to the modeling procedures used in prior sleep intervention research. This more robust
method of analysis identified improvements in some sleep parameters with virtual darkness
treatment. Future trials with larger samples should examine appropriate dosage (i.e., duration) of
virtual darkness treatment and the extent to which gains are sustained over time after cessation of
treatment.
Second, 96% (n = 23) of participants in this study were women, which did not allow for
comparison of virtual darkness efficacy and tolerability by gender. Gender differences in
disordered sleep have previously been identified. Women are more likely to report overall sleeprelated issues and demonstrate increased risk of developing insomnia compared to men
(Krishnan & Collop, 2006). Pharmacological sleep interventions may also require different
considerations for women compared to men. For instance, the Food and Drug Administration
recently issued guidelines indicating that the recommended zolpidem dosage for women should
be reduced by half due to differences in the speed of zolpidem metabolism between men and
women (Mallampalli & Carter, 2014). In contrast, men and women do not demonstrate
significant differences in treatment response to behavioral sleep interventions (Seyffert et al.,
2016; Trauer et al., 2015). Differences in treatment response by gender have not been examined
in previous trials of virtual darkness due to small sample sizes. Future studies should assess
whether treatment with virtual darkness produces differential effects for women compared to
men, or whether men and women may require different durations of treatment.
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Third, six participants demonstrated low adherence (43 to 77%) with completing the
daily sleep diaries, which may have impacted estimates of the mean and IIV of sleep parameters
for those participants. To address this issue, multilevel modeling procedures were used as they
are relatively robust to missing data compared to other statistical methods (Raudenbush & Bryk,
2002). Four participants demonstrated low adherence (57 to 77%) with completing nightly selfie
checks. While some participants demonstrated relatively low adherence to study procedures, the
average percentage of study procedures completed by all participants was 86.5%, with some
participants completing 100% of study procedures. Average rates of adherence in our sample
were similar to average rates of adherence to both CBT-I protocols (75%; Seyffert et al., 2016)
and pharmacological sleep interventions (83 to 98%; Zheng et al., 2020). MELSM results were
not significantly different when conducted with and without low compliance participants.
Findings provide support for the feasibility and efficacy of virtual darkness when participants are
asked to adhere to the treatment protocol in their home environment.
Finally, this study used self-report measures of sleep and mood. Self-reported sleep
ratings are important for assessing participants’ perception of their insomnia symptoms and
improvement during treatment. However, it is possible that the crossover from clear to ambertinted lenses could have created some expectancy for sleep improvement during the active
treatment phase, which may have impacted self-report ratings. Objective measures of sleep, such
as actigraphy, may be less influenced by these expectancy effects. Although correlations between
actigraphy and subjective report in estimating TST (r = .31 to .46) and WASO (r = .49) are often
low, concordance between methods in estimating sleep onset and wake times are typically high
(r > .70; Sadeh, 2011). Furthermore, actigraphy and subjective report may provide similar
estimates of changes in some sleep parameters following treatment (Smith et al., 2018). While
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these considerations provide support for concordance of subjective and objective measures of
sleep, future controlled trials may benefit from including objective measures of sleep as an
adjunct to self-reported sleep ratings.
Future Directions
Laboratory-based research has used dim light melatonin onset sampling procedures to
assess participants’ melatonin levels prior to sleep onset. These studies have indicated that the
use of blue-light blocking glasses effectively simulates dim lighting conditions and prevents
suppression of melatonin production prior to sleep onset (Figueiro & Overington, 2015; van der
Lely et al., 2015). However, dim light melatonin onset sampling has not yet been used to assess
changes in melatonin levels when participants are asked to adhere to a treatment protocol outside
of the laboratory. It may therefore be beneficial for future studies to conduct dim light melatonin
onset sampling to ensure that virtual darkness preserves melatonin production outside of a
laboratory setting.
Given that this was an initial feasibility trial, this study examined the short-term impact
of virtual darkness on insomnia symptoms with an active treatment duration of one to three
weeks. It is possible that longer treatment with virtual darkness may produce more pronounced
changes in sleep parameters. Future studies may benefit from extending the length of treatment,
examining insomnia relapse following treatment, and assessing whether treatment gains are
maintained at long-term follow-up (e.g., one year post-treatment).
Clinical Significance
While results of the present study should be interpreted in light of limitations, they
provide preliminary evidence supporting the feasibility and efficacy of a novel treatment option
for individuals with insomnia. In our sample, virtual darkness improved participants’ sleep
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quality, positive mood and calmness upon waking, and ability to fall asleep faster and remain
asleep with fewer nighttime awakenings. Given that virtual darkness is associated with minimal
adverse events, it may represent a beneficial adjunctive intervention to existing behavioral (e.g.,
CBT-I) or pharmacological interventions. The treatment was well tolerated, compliance was
comparable to other established treatments, and blue-light filtering glasses are highly accessible
and cost-effective, suggesting that virtual darkness may also be a beneficial primary intervention
for individuals with insomnia who have limited access to healthcare services. Randomized
controlled trials are required to replicate and extend the feasibility and efficacy findings reported
here.
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Appendix A: Tables

Age, M (SD)
Gender, n (%)
Female
Male
Race, n (%)
African American
American Indian/Alaskan Native
Asian/Pacific Islander
Caucasian
Other
Ethnicity, n (%)
Hispanic/Latino
Baseline Scores, M (SD)
PSQI Total Score
PANAS Positive
PANAS Negative
PVT Omission Errors
PVT Commission Errors
PVT Reaction Time (milliseconds)
PVT SD of Reaction Time
Post-Treatment Scores, M (SD)
PSQI Total Score
PANAS Positive
PANAS Negative

Characteristic

Characteristics of Enrolled Participants

Table 1

6 (100.00)
0 (0.00)
0 (0.00)
0 (0.00)
1 (16.67)
2 (33.33)
3 (50.00)
4 (66.67)
10.33 (3.67)
19.50 (6.72)
16.50 (5.99)
18.17 (11.20)
2.50 (1.76)
490.64 (75.97)
203.00 (155.34)
7.33 (4.08)
23.67 (10.37)
16.83 (8.16)

Total Sample
(N = 24)
20.08 (2.00)
23 (95.83)
1 (4.17)
4 (16.67)
1 (4.17)
7 (29.17)
7 (29.17)
5 (20.83)
10 (42.00)
10.42 (3.06)
24.63 (9.23)
13.92 (4.86)
12.16 (9.92) a
1.63 (1.50) a
450.53 (65.15) a
164.21 (117.02) a
5.95 (3.70) a
21.05 (8.77) a
14.79 (5.40) a
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Treatment
Group 1b
(n = 6)
20.17 (1.72)

5.00 (4.12)
29.80 (15.16)
14.20 (2.39)

10.20 (3.96)
26.80 (12.62)
17.00 (6.78)
5.40 (5.32)
1.40 (1.67)
418.76 (54.11)
167.47 (119.01)

2 (40.00)

0 (0.00)
0 (0.00)
2 (40.00)
2 (40.00)
1 (20.00)

5 (100.00)
0 (0.00)

Study Completers
Treatment
Group 2 b
(n = 5)
19.40 (1.14)

5.50 (3.34)
24.13 (4.58)
13.25 (3.62)

10.00 (2.14)
18.63 (6.50)
12.13 (3.00)
11.88 (9.14)
1.13 (.99)
440.28 (53.84)
133.08 (86.48)

4 (50.00)

2 (25.00)
1 (12.50)
3 (37.50)
1 (12.50)
1 (12.50)

7 (87.50)
1 (12.50)

Treatment
Group 3 b
(n = 8)
20.00 (2.62)

20.26 (18.12) a
1.32 (1.57) a
465.01 (77.49) a
121.51 (108.70) a
26.67 (17.01)
.83 (.75)
493.75 (63.85)
150.68 (145.77)

7.80 (7.76)
1.00 (1.00)
417.33 (34.42)
56.49 (16.97)

23.25 (21.13)
1.88 (2.17)
473.26 (97.17)
140.26 (104.35)
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weeks virtual darkness. Treatment Group 3 received one week placebo, three weeks virtual darkness.

Treatment Group 1 received three weeks placebo, one week virtual darkness. Treatment Group 2 received two weeks placebo, two

N = 19.

b

a

Note. PSQI = Pittsburgh Sleep Quality Index. PANAS = Positive and Negative Affect Schedule. PVT = Psychomotor Vigilance Task.

PVT Omission Errors
PVT Commission Errors
PVT Reaction Time (milliseconds)
PVT SD of Reaction Time

a

5 (21.7)
4 (17.4)
4 (17.4)
8 (34.8)
10 (43.5)
17 (73.9)
1 (4.3)
6 (26.1)
1 (4.3)
7 (30.4)
2 (8.7)

4 (16.7)
4 (16.7)
5 (20.8)
12 (50.0)
11 (45.8)
18 (75.0)
3 (12.5)
8 (33.3)
7 (29.2)
9 (37.5)
0 (0.0)

8 (42.1)
13 (68.4)
0 (0.0)
3 (15.8)
2 (10.5)
7 (36.8)
0 (0.0)

3 (15.8)
2 (10.5)
3 (15.8)
3 (15.8)

Virtual Darkness
(N = 19)
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Other side effects included: skin irritation where the study glasses rested on the side of the face (n = 1) and “double vision” (n = 1).

Adverse Event
Eye strain, n (%)
Dry eyes, n (%)
Blurred vision, n (%)
Headaches, head pain, or head
pressure, n (%)
Morning grogginess, n (%)
Daytime sleepiness, n (%)
Vertigo, n (%)
Irritability, n (%)
Stomach pain, n (%)
Vivid dreams, n (%)
Other, n (%)a

Placebo
(N = 23)

Baseline
(N = 24)

Number and Percentage of Participants Reporting Adverse Events by Phase of Study

Table 2

a

Virtual Darkness
(N = 19)
M (SD)
7.30 (2.21)
81.87 (20.2)
17.92 (21.93)
1.32 (1.32)
2.30 (.87)
9.69 (2.65)
7.88 (2.96)
9.51 (2.79)
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Higher scores indicate greater positive mood valence, greater energy, and greater calmness, respectively.

Sleep or Mood Variable
Total sleep time (hours)
Sleep efficiency (%)
Sleep onset latency (minutes)
Number of wakings after sleep onset
Sleep quality
Mood upon wakinga
Energy upon wakinga
Calmness upon wakinga

Placebo
(N = 19)
M (SD)
7.42 (2.39)
84.26 (19.41)
25.21 (22.02)
1.37 (1.57)
2.06 (.73)
8.55 (2.38)
7.34 (2.91)
8.61 (2.66)

Grand Means and Standard Deviations of Sleep Parameters and Mood Upon Waking by Study Phase

Table 3

*

*
*

*
*

Main Effect
*

Random
Scale Effect
*
*
*
*
*
*
*
*
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* denotes a significant finding for each level of the MELSM analyses.

Outcome Variable
Total Sleep Time
Sleep Onset Latency
Wakings After Sleep Onset
Sleep Efficiency
Sleep Quality
Mood Upon Waking
Energy Upon Waking
Calmness Upon Waking

Intraindividual
Variability

Overview of Significant Findings from Mixed-Effect Location-Scale Models

Table 4

*
*
*

Random
Location
Effect

23.49 (2.93)*
-6.10 (1.91)*
-.08 (.14)
4.84 (.39)*
-.42 (.33)
-.03 (.03)
5.20 (.35)*
-.63 (.25)*
.03 (.02)
.93 (.18)*
1.04 (.22)*

7.27 (.33)*
.06 (.24)
-.002 (.02)
.51 (.42)
.33 (.47)
-.08 (.06)
1.06 (.18)*
.11 (.21)
-.02 (.02)
.55 (.12)*
-.31 (.16)

SOL
Estimate
(Standard Error)

4.31 (.28)*
-.01 (.23)
.001 (.02)
.57 (.16)*
-.90 (.28)*

4.60 (.65)*
.70 (.38)
.02 (.03)

84.91 (2.60)*
-2.38 (1.88)
-.07 (.14)

SE
Estimate
(Standard Error)

.08 (.25)
-.39 (.22)
-.002 (.02)
.76 (.15)*
.57 (.22)*

-.15 (.37)
-.33 (.25)
-.001 (.02)

1.52 (.23)*
-.39 (.13)*
.01 (.01)

WASO
Estimate
(Standard Error)

-.84 (.14)*
.05 (.22)
.01 (.02)
.38 (.11)*
.06 (.12)

-2.92 (.55)*
1.16 (.62)
.03 (.04)

2.03 (.07)*
.35 (.11)*
-.001 (.01)

Sleep Quality
Estimate
(Standard Error)

*p < .05.

Number of Wakings After Sleep Onset.
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Note. IIV = Intra-Individual Variability. TST = Total Sleep Time. SOL = Sleep Onset Latency. SE = Sleep Efficiency. WASO =

Variable
Mean level (β)
Intercept
Study phase
Day x Study phase
Between-subjects variance ratio
(α)
Intercept
Study phase
Day x Study phase
IIV (within-subjects variance
ratio; τ)
Intercept
Study phase
Day x Study phase
Random scale standard deviation
Random location (mean) effect
on IIV

TST
Estimate
(Standard Error)

Mixed-Effect Location-Scale Model Results Assessing the Impact of Virtual Darkness Treatment on Sleep Parameters

Table 5

.78 (.45)
-.13 (.46)
-.01 (.04)
1.56 (.21)*
-.28 (.22)
.02 (.02)
.75 (.14)*
-.10 (.20)

.52 (.40)
-.07 (.31)
.01 (.02)
1.30 (.21)*
-.06 (.22)
.01 (.02)
.78 (.15)*
-.04 (.21)

* p < .05.
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8.83 (.38)*
.75 (.24)*
-.01 (.02)

8.82 (.33)*
.85 (.24)*
-.01 (.02)

Note. IIV = Intra-Individual Variability.

Variable
Mean level (β)
Intercept
Study phase
Day x Study phase
Between-subjects variance ratio
(α)
Intercept
Study phase
Day x Study phase
IIV (within-subjects variance
ratio; τ)
Intercept
Study phase
Day x Study phase
Random scale standard deviation
Random location (mean) effect
on IIV

Calmness Upon
Waking
Estimate
(Standard Error)

Mood Valence
Upon Waking
Estimate
(Standard Error)

1.72 (.21)*
-.13 (.22)
.01 (.02)
.73 (.14)*
.25 (.20)

.51 (.41)
.33 (.41)
-.04 (.04)

7.38 (.35)*
.55 (.31)
-.0002 (.03)

Energy Upon
Waking
Estimate
(Standard Error)

Mixed-Effect Location-Scale Model Results Assessing the Impact of Virtual Darkness Treatment on Mood Valence, Calmness, and
Energy Upon Waking

Table 6
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Appendix B: Figures

Study Procedures

Figure 1
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Total Sleep Time by Treatment Group and Week of Study

Figure 2
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Sleep Onset Latency by Treatment Group and Week of Study

Figure 3

60

Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Number of Wakings After Sleep Onset by Treatment Group and Week of Study

Figure 4
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Sleep Efficiency by Treatment Group and Week of Study

Figure 5
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Sleep Quality by Treatment Group and Week of Study

Figure 6
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Energy Upon Waking by Treatment Group and Week of Study

Figure 7
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Calmness Upon Waking by Treatment Group and Week of Study

Figure 8
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Note. Vertical line denotes the week in which each treatment group switched from placebo to virtual darkness treatment.

Mood Upon Waking by Treatment Group and Week of Study

Figure 9
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presented at the 2018 Graduate and Professional Student Research Forum, University of
Nevada, Las Vegas
*1st Place Poster Presentation
10. Kondo, D. G., Huber, R., Shi, X., Sung, Y. H., Prescot, A., Fiedler, K., Hellem, T., Sherwood,
S. N., Forrest, L., Boxer, D., & Renshaw, P. F. (2017, November). Clinical and Imaging
Studies of Uridine: A Rapid Treatment for Suicidal Ideation via Shared Mechanisms with
Ketamine and Lithium. Poster presented at the 2017 IASR/AFSP International Summit on
Suicide Research, Henderson, NV
*Honorable Mention Poster Presentation
9. Sherwood, S. N., Greenway, J., Freeman, A. J. (2017, November). Trends in Pediatric Mood
Disorder Diagnosis in a Nevada Medicaid Population between 2005 and 2015. Poster
presented at the 2017 Association of Behavioral and Cognitive Therapies Annual
Convention, San Diego, CA
8. Ibarra, M., Rogers, E., Santarsierri, B., Sherwood, S. N., Chen, Y. L., & Freeman, A. J. (2017,
November). Gender, Chronotype, and Affective Symptoms. Poster presented at the 2017
Association of Behavioral and Cognitive Therapies Annual Convention, San Diego, CA
7. Sherwood, S. N., Chen, Y., & Freeman, A. J. (2017, August). Chronotype Does Not Predict NonSuicidal Self-Injury. Poster presented at the 2017 American Psychological Association
Annual Convention, Washington, D.C.
6. Chen, Y., Sherwood, S. N., & Freeman, A. J. (2017, August). Cultural Differences in Mania:
Gender but not Ethnicity Matters. Poster presented at the 2017 American Psychological
Association Annual Convention, Washington, D.C.
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5. Diaz, V., Chen, Y., Saucedo, M., Sherwood, S. N., & Freeman, A. J. (2017, August). The
Relationship between Irritability, Mood and Anxiety in College Students. Poster presented at
the 2017 American Psychological Association Annual Convention, Washington, D.C.
4. Sherwood, S. N., Forrest, L. N., Huber, R. S., Renshaw, P. F., & Kondo, D. G. (2016, April).
Perfectionism in Adolescents with Treatment-Resistant Depression and Healthy Comparison
Subjects. Poster presented at the 2016 Western Psychological Association Conference, Long
Beach, CA
3. Scholl, L. S., Bakian, A. V., Huber, R. S., Sherwood, S. N., Kondo, D. G., & Renshaw, P. F.
(2016, May). Frequency of Anxious Feelings Linked with Altitude of Residence. Poster
presented at the 2016 Association for Psychological Science Convention, Chicago, IL
2. Sherwood, S. N., Forrest, L. N., Scholl, L. S., Huber, R. S., Renshaw, P. F., & Kondo, D. G.
(2015, September). Perfectionism and Treatment Response in Adolescent Females with
Treatment-Resistant Major Depressive Disorder. Poster presented at the 2015 Utah Science
Technology and Research initiative (USTAR) Confluence, Salt Lake City, UT
1. Kuykendall, D., Sherwood, S., Kondo, D. G., Scholl, L., & Renshaw, P. F. (2014, November).
Major depressive disorder’s association with altitude of residence by county in the United
States for 2012. Poster presented at the 2014 American Public Health Association’s Annual
Meeting and Exposition, New Orleans, LA
RESEARCH EXPERIENCE
Graduate Research Assistant and Lab Coordinator
Development of Irritability, Mood and Emotions Lab
University of Nevada, Las Vegas
Primary Advisor: Andrew J. Freeman, Ph.D.

August 2016 – December 2020

Project 1: Trends in the Rate of Inpatient Pediatric Bipolar Disorder Diagnosis Between 1996 and
2015
Project 2: Virtual Darkness for Young Adult Sleep Difficulties
Project 3: Irritability, Distress, and Internalizing Symptoms
Responsibilities: 1) Lab coordinator and project manager for studies examining a novel treatment for
insomnia disorder as well as the assessment of pediatric mood and externalizing problems; 2)
Development of data management tools and procedures; 3) Data management and analysis; 4)
Preparation of manuscripts and conference submissions; 5) Development of new study protocols and
materials; 6) Development of Institutional Review Board submission materials; 7) Recruitment,
training, and supervision of study personnel; 8) Participant recruitment, consent, and evaluation
Clinical Research Coordinator
May 2014 – August 2016
The Brain Institute, Department of Diagnostic Neuroimaging
University of Utah
Primary Advisors: Perry F. Renshaw, M.D., Ph.D., M.B.A.; Douglas G. Kondo, M.D.
Project 1: Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females with
Treatment-Resistant Major Depressive Disorder: A Magnetic Resonance Spectroscopy Study
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Project 2: Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel
Project 3: Placebo Controlled Study of Uridine for Adolescent Bipolar Depression: A Magnetic
Resonance Spectroscopy Study
Responsibilities: 1) Managed operations for randomized controlled trials evaluating novel
interventions for bipolar disorder and treatment-refractory major depressive disorder among youth
and young adults; 2) Developed data management tools, managed data, and conducted analyses; 3)
Prepared manuscripts and grant applications; 4) Prepared regulatory materials and annual reports for
the Food and Drug Administration, Institutional Review Board, National Institute of Mental Health
(funding source), and Data Safety and Monitoring Board; 5) Supervised and trained study personnel;
6) Acquired experimental study drug from manufacturer and dispensed study medication; 7)
Coordinated with university pharmacy to set up blinding procedures for study drug; 8) Participant
recruitment and consent; 9) Administered the Structured Clinical Interview for DSM-IV and weekly
mood rating scales (e.g., Children’s Depression Rating Scale-Revised) for adolescents and young
adults with unipolar depressive disorders and bipolar spectrum disorders

Research Assistant
August 2013 – May 2014
Risk to Resilience Lab, Department of Psychology, University of Utah
Salt Lake County Juvenile Detention Center, West Valley City, Utah
Primary Advisor: Patricia Kerig, Ph.D.
Project: Investigating the Mechanisms Linking Trauma and Youth Antisocial Behavior
Responsibilities: 1) Obtained informed consent from parents of youth held at the Salt Lake City
Juvenile Detention Center to participate in a study examining risk and resilience factors for
psychopathology among detained youth; 2) Guided youth through study protocol using
questionnaires and psychophysiological equipment
Field Research Assistant
Department of Family and Consumer Studies, University of Utah
Department of Psychology, University of Utah
Primary Advisor: Carroll Werner, Ph.D.

May 2013 – May 2014

Project: Moving Across Places Study
Responsibilities: 1) Worked independently to complete field ratings for a study examining the
relationship between walkability of neighborhoods and activity level of neighborhood residents;
2) Participated in frequent trainings to ensure interrater reliability with other study staff members
Research Assistant
Applied Cognition Lab, Department of Psychology, University of Utah
Primary Advisor: David Strayer, Ph.D.

May 2012 – May 2014

Project: Measuring Cognitive Distraction in the Automobile
Responsibilities: 1) Obtained informed consent for a study examining distracted driving among
young adults; 2) Guided participants through study protocol using questionnaires and
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psychophysiological equipment; 3) Recruited and trained new research assistants; 4) Set up and
maintained psychophysiological equipment; 5) Collected, entered, and coded data; 6) Recruited
participants
PRE-DOCTORAL PRACTICUM TRAINING
Cure 4 The Kids Foundation
Las Vegas, Nevada
Doctoral Practicum Student
Supervisor: Danielle T. Bello, Ph.D.

August 2020 – May 2021
16-20 hours per week

Provide comprehensive neuropsychological assessments and write integrated reports in a pediatric
outpatient hospital setting. Patients are children, adolescents, and young adults referred from
oncology, hematology, rheumatology, and genetic disorder clinics. Common psychological diagnoses
include cognitive disabilities, neurodevelopmental disorders, learning disorders, anxiety disorders,
depressive disorders, and attention deficit/hyperactivity disorder. Provide consultation-liaison
services to address adjustment, anxiety, depression, sleep, behavior management, medical adherence,
and parent training concerns. Consultation services are provided during chemotherapy infusion
appointments for youth currently receiving cancer treatment and long-term follow-up clinics for
survivors of cancer.
The Evidence Based Practice of Nevada
August 2019 – July 2020
Las Vegas, Nevada
16-20 hours per week
Doctoral Practicum Student
Supervisor: Adrianna Wechsler Zimring, Ed.M., Ph.D.
Rotation: Pediatric Neuropsychological and Psychoeducational Evaluation
Provided evidence-based neuropsychological assessment services for children, adolescents, and
young adults in an outpatient behavioral healthcare setting. Completed comprehensive evaluations
from start to finish for youth with a variety of developmental, cognitive, mood, behavioral, and
educational concerns. Comprehensive evaluation process included: intake and psychiatric interview;
selection of appropriate test battery; test administration, scoring, and interpretation; integrated report
writing; and providing feedback to youth and parents. Co-facilitated weekly parent management
training and pediatric anxiety treatment groups via telehealth.
UNLV Child School Refusal and Anxiety Disorders Clinic
Las Vegas, NV
Doctoral Practicum Student
Supervisor: Christopher Kearney, Ph.D.

February 2019 – May 2019
5 hours per week

Co-facilitated a weekly family-based group for youth with selective mutism and their caregivers. The
group involved a parent training portion and a child behavioral treatment portion, with a focus on
evidence-supported techniques such as exposure, anxiety management, problem-solving, and schoolbased intervention. Services were provided to diverse populations of children between the ages of 4-8
years.
Desert Willow Treatment Center
Las Vegas, NV

August 2018 – August 2019
15 hours per week
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Doctoral Practicum Student
Supervisor: Caron Evans, Ph.D.
Provided evidence-based assessment and intervention services for adolescents on acute and
residential psychiatric inpatient units. Conducted weekly individual and family therapy to address a
range of behavioral and emotional concerns (e.g., depression, bipolar disorder, suicidal ideation,
oppositional behavior, etc.). Worked collaboratively with patients and families to identify acute or
long-term treatment goals. Completed comprehensive integrated assessment reports and feedback
sessions with adolescents and caregivers. Participated in weekly treatment team meetings with a
multidisciplinary team including psychiatrists, psychologists, social workers, nurses, psychiatric case
workers, and caregivers.
The PRACTICE Community Mental Health Clinic
Department of Psychology, UNLV
Doctoral Practicum Student
Supervisors: Rachele Merk, Ph.D.; Michelle G. Paul, Ph.D.

August 2017 – June 2018
20 hours per week

Provided evidence-based therapeutic services to children and adolescents with a range of behavioral
and emotional concerns (e.g., ADHD, Tourette’s disorder, trichotillomania, perfectionism, anxiety,
depression, oppositional behavior, etc.) at a campus-based community mental health clinic. Provided
psychological assessment services for a variety of concerns, including learning difficulties, academic
achievement and cognitive ability, and psychodiagnostic clarification. Completed comprehensive
integrated assessment reports and provided feedback and direction to clients and families. Conducted
bi-weekly new client intakes, case presentations at treatment team meetings, and follow-up intakes.
TEACHING EXPERIENCE
Instructor of Record
University of Nevada, Las Vegas
Courses:
PSY 341 – Abnormal Psychology, 2 sections

Fall 2020

Developed a 16-week curriculum for topics in abnormal psychology (online format). Developed
syllabi, assignments, activities, and exams designed to assess and facilitate critical thinking skills and
maximize online learning.
Instructor of Record
University of Nevada, Las Vegas
Courses:
PSY 101 – General Psychology, 2 sections per semester
PSY 341 – Abnormal Psychology, 2 sections per semester

Fall 2019 – Spring 2020

Developed a 16-week curriculum for topics in introductory psychology (in-person format) and
abnormal psychology (online format). Delivered bi-weekly lectures and utilized the MindTap
learning platform to integrate technology and enhance student engagement. Developed syllabi,
assignments, activities, and exams designed to assess and facilitate critical thinking skills.
Instructor of Record

Fall 2018 – Spring 2019
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University of Nevada, Las Vegas
Supervisor: Wayne Weiten, Ph.D.
Courses:
PSY 101 – General Psychology, 2 sections per semester
Developed a 16-week curriculum for introductory topics in physiological psychology, research
methods, learning, personality, development, social behavior, history, and psychological disorders.
Delivered bi-weekly lectures and utilized the MindTap learning platform to integrate technology and
enhance student engagement. Developed syllabi, assignments, activities, and exams designed to
assess and facilitate critical thinking skills. Concurrently enrolled in Teaching of Psychology with a
supervisory component for the initial semester of teaching.
Graduate Teaching Assistant
University of Nevada, Las Vegas
Supervisor: Diane Villa, Ph.D.
Courses:
PSY 316 – Cognitive Psychology, 2 sections per semester
PSY 341 – Abnormal Psychology, 1 section per semester
PSY 438 – Child Behavior Disorders, 1 section
COLA 100LA – First Year Seminar, 1 section

Fall 2017 – Spring 2018

Facilitated weekly office hours to address student questions and concerns. Graded student projects,
research papers, and other assignments. Provided feedback to students regarding mastery of course
material and improving academic writing abilities and study skills.
Graduate Teaching Assistant
University of Nevada, Las Vegas
Supervisor: Andrew J. Freeman, Ph.D.
Course:
PSY 341 – Abnormal Psychology, 1 section

Spring 2017

Graded student projects, research papers, and other assignments. Provided feedback to students
regarding mastery of course material and improving academic writing abilities and study skills.
SCHOLARSHIPS AND AWARDS
2020
2020
2020-2021
2019-2020
2019-2020
2019
2019
2019
2018-2019

Summer Doctoral Research Fellowship, UNLV
1st Place Poster Presentation, UNLV Graduate Research Forum
Patricia Sastaunik Scholarship, UNLV
Graduate Access Grant, UNLV
Patricia Sastaunik Scholarship, UNLV
Psi Chi APA Society Convention Research Award, American Psychological
Association Annual Convention
Outstanding Student Poster Focused on Assessment and Emerging Leaders in
Assessment Award, American Psychological Association Annual Convention (award
sponsored by APA Divisions 5, 12, and 40)
Graduate College Summer Session Scholarship, UNLV
Patricia Sastaunik Scholarship, UNLV
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2018-2019
2018
2018
2018
2018
2017-2019
2017
2012-2014

Graduate Access Grant, UNLV
Johnson Youngstrom Prize for Outstanding Student Poster, Association for
Behavioral and Cognitive Therapies 52nd Annual Convention
1st Place Poster Presentation, UNLV Graduate Research Forum
Summer Research Stipend Award, UNLV College of Liberal Arts
Graduate College Summer Session Scholarship, UNLV
Conference Travel Awards, 5 Total Awards, UNLV
Honorable Mention Poster Presentation, International Summit on Suicide
Dean’s List, University of Utah

LEADERSHIP AND SERVICE
Chair
Cohort Representative
Clinical Student Committee
University of Nevada, Las Vegas

May 2019 – May 2020
May 2018 – Present

In-Service Instructor
Desert Willow Treatment Center
Las Vegas, NV

April 2019

Group Leader
Interprofessional Education Program
University of Nevada, Las Vegas

March 2019

Invited Panelist
Graduate School in Psychology Informational Session
Nevada State College
Graduate Mentor
Outreach for Undergraduates Mentorship Program
University of Nevada, Las Vegas

September 2016

August 2016 – May 2017

PROFESSIONAL TRAINING
Not All that Blows up is Bipolar: Evidence-Based Assessment and Treatment
Fall 2019
for Bipolar Disorder in Youth and Young Adults
Instructor: Eric Youngstrom, Ph.D.
One-day workshop with instruction in the use of evidence-based, practical assessment techniques to
improve efficiency and accuracy of pediatric bipolar disorder diagnosis. Information regarding
biological and psychological treatments for bipolar disorder was provided with an emphasis on what
non-prescribing clinicians need to know about these interventions.
Professional Development in Psychology
Fall 2019
Instructors: Mitch Prinstein, Ph.D. and Eric Youngstrom, Ph.D.
One-day student-focused professional development workshop providing training in a variety of
professional development topics such as acquiring a career in an academic setting, grant writing, and
dissemination of scientific findings to a broader audience via online platforms.
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Comprehensive Dialectical Behavior Therapy (DBT) Workshop: Part II
Fall 2019
Instructor: Armida Fruzzetti, Ph.D.
Three-day workshop with instruction in the use of DBT to treat emotion dysregulation. Workshop
included live, guided practice (e.g., role plays) in the use of DBT skills, skill training, and skill
coaching with a particular focus on how to implement these skills in individual therapy, group
therapy, and as part of a DBT consultation team.
Comprehensive Dialectical Behavior Therapy (DBT) Workshop: Part I
Fall 2019
Instructor: Alan Fruzzetti, Ph.D.
Three-day live workshop with instruction in the use of DBT to treat emotion dysregulation. Areas of
training included theory, treatment structure, intervention targets, and treatment strategies.
Acceptance and Commitment Therapy (ACT) Workshop
Fall 2018
Instructor: Steven Hayes, Ph.D.
Two-day live workshop with instruction in the use of ACT to treat a variety of psychological
problems. Areas of training included theory and proposed mechanisms of change, instruction on
specific ACT skills, and guided role-playing of ACT delivery.
Interprofessional Education Program
Spring 2018 & 2019
Supervisor: Michelle Paul, Ph.D.
Two annual eight-hour workshops aimed at increasing awareness of interprofessional education,
practice concepts, roles, and responsibilities for the participating healthcare professions with the goal
of understanding how integrated health teams should function to better serve patients.
Integrated Behavioral Health in Primary Care Course
Fall 2017
Instructor: Sara Hunt, Ph.D.
Sixteen-week course developed based on recommendations from the Interprofessional Education
Collaborative for clinical professions who plan on delivering integrated behavioral health services.
Areas of training included assessment, intervention, consultation, and working within an
multidisciplinary team. Emphasis areas of the course included populations with complex needs in
both physical and mental health (e.g., pediatric chronic pain patients).
Regression Workshop
May 2017
Instructor: Andrew J. Freeman, Ph.D.
Comprehensive 6-day workshop on regression and use of R statistical programming for data analysis.
Clinical Research Certificate
Research Administration and Training Series, University of Utah

May 2015

PROFESSIONAL AFFILIATIONS
APA Division 54, Society of Pediatric Psychology
APA Division 12, Society of Clinical Psychology (SCP)
Association for Psychological Science (APS), Student Affiliate
Association for Behavioral and Cognitive Therapies (ABCT), Student Member
American Psychological Association (APA), Student Member
American Psychological Association of Graduate Students (APAGS)
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2020 – Present
2019 – Present
2017 – 2019
2017 – Present
2016 – Present
2016 – Present

APA Division 53, Society of Clinical Child & Adolescent Psychology (SCCAP)
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2015 – Present

